

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent developments in the treatment of Parkinson's... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/9-862/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/9-862" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent developments in the treatment of Parkinson's Disease" />
    
            <meta name="og:title" content="F1000Research Article: Recent developments in the treatment of Parkinson's Disease.">
            <meta name="og:description" content="Read the latest article version by Thomas B Stoker, Roger A Barker, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="28292">
            <meta name="article-id" content="25634">
            <meta name="dc.title" content="Recent developments in the treatment of Parkinson's Disease">
            <meta name="dc.description" content="Parkinson&rsquo;s disease (PD) is a common neurodegenerative disease typified by a movement disorder consisting of bradykinesia, rest tremor, rigidity, and postural instability. Treatment options for PD are limited, with most of the current approaches based on restoration of dopaminergic tone in the striatum. However, these do not alter disease course and do not treat the non-dopamine-dependent features of PD such as freezing of gait, cognitive impairment, and other non-motor features of the disorder, which often have the greatest impact on quality of life. As understanding of PD pathogenesis grows, novel therapeutic avenues are emerging. These include treatments that aim to control the symptoms of PD without the problematic side effects seen with currently available treatments and those that are aimed towards slowing pathology, reducing neuronal loss, and attenuating disease course. In this latter regard, there has been much interest in drug repurposing (the use of established drugs for a new indication), with many drugs being reported to affect PD-relevant intracellular processes. This approach offers an expedited route to the clinic, given that pharmacokinetic and safety data are potentially already available. In terms of better symptomatic therapies that are also regenerative, gene therapies and cell-based treatments are beginning to enter clinical trials, and developments in other neurosurgical strategies such as more nuanced deep brain stimulation approaches mean that the landscape of PD treatment is likely to evolve considerably over the coming years. In this review, we provide an overview of the novel therapeutic approaches that are close to, or are already in, clinical trials.">
            <meta name="dc.subject" content="&alpha;-synuclein; deep brain stimulation; drug repurposing; immunotherapies; gene therapies; neural grafting; Parkinson&rsquo;s disease">
            <meta name="dc.creator" content="Stoker, Thomas B">
            <meta name="dc.creator" content="Barker, Roger A">
            <meta name="dc.date" content="2020/07/31">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.25634.1">
            <meta name="dc.source" content="F1000Research 2020 9:862">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="&alpha;-synuclein; deep brain stimulation; drug repurposing; immunotherapies; gene therapies; neural grafting; Parkinson&rsquo;s disease">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2020/07/31">
            <meta name="prism.volume" content="9">
            <meta name="prism.number" content="862">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.25634.1">
            <meta name="prism.url" content="https://f1000research.com/articles/9-862">
            <meta name="citation_title" content="Recent developments in the treatment of Parkinson's Disease">
            <meta name="citation_abstract" content="Parkinson&rsquo;s disease (PD) is a common neurodegenerative disease typified by a movement disorder consisting of bradykinesia, rest tremor, rigidity, and postural instability. Treatment options for PD are limited, with most of the current approaches based on restoration of dopaminergic tone in the striatum. However, these do not alter disease course and do not treat the non-dopamine-dependent features of PD such as freezing of gait, cognitive impairment, and other non-motor features of the disorder, which often have the greatest impact on quality of life. As understanding of PD pathogenesis grows, novel therapeutic avenues are emerging. These include treatments that aim to control the symptoms of PD without the problematic side effects seen with currently available treatments and those that are aimed towards slowing pathology, reducing neuronal loss, and attenuating disease course. In this latter regard, there has been much interest in drug repurposing (the use of established drugs for a new indication), with many drugs being reported to affect PD-relevant intracellular processes. This approach offers an expedited route to the clinic, given that pharmacokinetic and safety data are potentially already available. In terms of better symptomatic therapies that are also regenerative, gene therapies and cell-based treatments are beginning to enter clinical trials, and developments in other neurosurgical strategies such as more nuanced deep brain stimulation approaches mean that the landscape of PD treatment is likely to evolve considerably over the coming years. In this review, we provide an overview of the novel therapeutic approaches that are close to, or are already in, clinical trials.">
            <meta name="citation_description" content="Parkinson&rsquo;s disease (PD) is a common neurodegenerative disease typified by a movement disorder consisting of bradykinesia, rest tremor, rigidity, and postural instability. Treatment options for PD are limited, with most of the current approaches based on restoration of dopaminergic tone in the striatum. However, these do not alter disease course and do not treat the non-dopamine-dependent features of PD such as freezing of gait, cognitive impairment, and other non-motor features of the disorder, which often have the greatest impact on quality of life. As understanding of PD pathogenesis grows, novel therapeutic avenues are emerging. These include treatments that aim to control the symptoms of PD without the problematic side effects seen with currently available treatments and those that are aimed towards slowing pathology, reducing neuronal loss, and attenuating disease course. In this latter regard, there has been much interest in drug repurposing (the use of established drugs for a new indication), with many drugs being reported to affect PD-relevant intracellular processes. This approach offers an expedited route to the clinic, given that pharmacokinetic and safety data are potentially already available. In terms of better symptomatic therapies that are also regenerative, gene therapies and cell-based treatments are beginning to enter clinical trials, and developments in other neurosurgical strategies such as more nuanced deep brain stimulation approaches mean that the landscape of PD treatment is likely to evolve considerably over the coming years. In this review, we provide an overview of the novel therapeutic approaches that are close to, or are already in, clinical trials.">
            <meta name="citation_keywords" content="&alpha;-synuclein; deep brain stimulation; drug repurposing; immunotherapies; gene therapies; neural grafting; Parkinson&rsquo;s disease">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Thomas B Stoker">
            <meta name="citation_author_institution" content="John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Forvie Site, Robinson Way, Cambridge, CB2 0PY, UK">
            <meta name="citation_author_institution" content="Department of Neurology, Norfolk and Norwich University Hospital, Norwich, UK">
            <meta name="citation_author" content="Roger A Barker">
            <meta name="citation_author_institution" content="Wellcome Trust &ndash; Medical Research Council Stem Cell Institute, University of Cambridge, Cambridge, UK">
            <meta name="citation_author_institution" content="John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Forvie Site, Robinson Way, Cambridge, CB2 0PY, UK">
            <meta name="citation_publication_date" content="2020/07/31">
            <meta name="citation_volume" content="9">
            <meta name="citation_publication_number" content="862">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.25634.1">
            <meta name="citation_firstpage" content="862">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/9-862/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/9-862.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=28292 /> <input type=hidden id=articleId name=articleId value=25634 /> <input type=hidden id=xmlUrl value="/articles/9-862/v1/xml"/> <input type=hidden id=xmlFileName value="-9-862-v1.xml"> <input type=hidden id=article_uuid value=c706e5aa-67f6-4d88-9eaf-602285070cca /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent developments in the treatment of Parkinson's Disease"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.25634.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.25634.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/9-862"
  },
  "headline": "Recent developments in the treatment of Parkinson's Disease",
  "datePublished": "2020-07-31T12:18:12",
  "dateModified": "2020-07-31T12:18:12",
  "author": [
    {
      "@type": "Person",
      "name": "Thomas B Stoker"
    },    {
      "@type": "Person",
      "name": "Roger A Barker"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Parkinson&rsquo;s disease (PD) is a common neurodegenerative disease typified by a movement disorder consisting of bradykinesia, rest tremor, rigidity, and postural instability. Treatment options for PD are limited, with most of the current approaches based on restoration of dopaminergic tone in the striatum. However, these do not alter disease course and do not treat the non-dopamine-dependent features of PD such as freezing of gait, cognitive impairment, and other non-motor features of the disorder, which often have the greatest impact on quality of life. As understanding of PD pathogenesis grows, novel therapeutic avenues are emerging. These include treatments that aim to control the symptoms of PD without the problematic side effects seen with currently available treatments and those that are aimed towards slowing pathology, reducing neuronal loss, and attenuating disease course. In this latter regard, there has been much interest in drug repurposing (the use of established drugs for a new indication), with many drugs being reported to affect PD-relevant intracellular processes. This approach offers an expedited route to the clinic, given that pharmacokinetic and safety data are potentially already available. In terms of better symptomatic therapies that are also regenerative, gene therapies and cell-based treatments are beginning to enter clinical trials, and developments in other neurosurgical strategies such as more nuanced deep brain stimulation approaches mean that the landscape of PD treatment is likely to evolve considerably over the coming years. In this review, we provide an overview of the novel therapeutic approaches that are close to, or are already in, clinical trials."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/9-862/v1",
            "name": "Recent developments in the treatment of Parkinson's Disease"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent developments in the treatment of Parkinson's Disease </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=28292 data-id=25634 data-downloads="" data-views="" data-scholar="10.12688/f1000research.25634.1" data-recommended="" data-doi="10.12688/f1000research.25634.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/9-862/v1/pdf?article_uuid=c706e5aa-67f6-4d88-9eaf-602285070cca" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-25634-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-25634-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-25634-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Stoker TB and Barker RA. Recent developments in the treatment of Parkinson's Disease [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(Faculty Rev):862 (<a class=new-orange href="https://doi.org/10.12688/f1000research.25634.1" target=_blank>https://doi.org/10.12688/f1000research.25634.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-25634-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=25634 id=track-article-signin-25634 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/25634?target=/articles/9-862/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=28292 /> <input name=articleId type=hidden value=25634 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent developments in the treatment of Parkinson's Disease</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:tbs26@cantab.net" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Thomas B Stoker</span></a><a href="https://orcid.org/0000-0001-5186-7630" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-5186-7630</div><sup>1,2</sup>,&nbsp;</span><span class="">Roger A Barker<sup>1,3</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:tbs26@cantab.net" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Thomas B Stoker</span></a><a href="http://orcid.org/0000-0001-5186-7630" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-5186-7630</div><sup>1,2</sup>,&nbsp;</span><span class="">Roger A Barker<sup>1,3</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 31 Jul 2020 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.25634.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Forvie Site, Robinson Way, Cambridge, CB2 0PY, UK<br/> <sup>2</sup> Department of Neurology, Norfolk and Norwich University Hospital, Norwich, UK<br/> <sup>3</sup> Wellcome Trust &ndash; Medical Research Council Stem Cell Institute, University of Cambridge, Cambridge, UK<br/> <p> <div class=margin-bottom> Thomas B Stoker <br/> <span>Roles: </span> Conceptualization, Writing  Original Draft Preparation, Writing  Review & Editing </div> <div class=margin-bottom> Roger A Barker <br/> <span>Roles: </span> Conceptualization, Supervision, Writing  Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=34838-68463></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=73309-68462></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Parkinsons disease (PD) is a common neurodegenerative disease typified by a movement disorder consisting of bradykinesia, rest tremor, rigidity, and postural instability. Treatment options for PD are limited, with most of the current approaches based on restoration of dopaminergic tone in the striatum. However, these do not alter disease course and do not treat the non-dopamine-dependent features of PD such as freezing of gait, cognitive impairment, and other non-motor features of the disorder, which often have the greatest impact on quality of life. As understanding of PD pathogenesis grows, novel therapeutic avenues are emerging. These include treatments that aim to control the symptoms of PD without the problematic side effects seen with currently available treatments and those that are aimed towards slowing pathology, reducing neuronal loss, and attenuating disease course. In this latter regard, there has been much interest in drug repurposing (the use of established drugs for a new indication), with many drugs being reported to affect PD-relevant intracellular processes. This approach offers an expedited route to the clinic, given that pharmacokinetic and safety data are potentially already available. In terms of better symptomatic therapies that are also regenerative, gene therapies and cell-based treatments are beginning to enter clinical trials, and developments in other neurosurgical strategies such as more nuanced deep brain stimulation approaches mean that the landscape of PD treatment is likely to evolve considerably over the coming years. In this review, we provide an overview of the novel therapeutic approaches that are close to, or are already in, clinical trials. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> -synuclein; deep brain stimulation; drug repurposing; immunotherapies; gene therapies; neural grafting; Parkinsons disease </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Thomas B Stoker (<a href="mailto:tbs26@cantab.net">tbs26@cantab.net</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Thomas B Stoker </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The authors acknowledge financial support from the following organisations: Medical Research Council and Wellcome Trust Stem Cell Institute (Cambridge 203151/Z/16/Z), National Institute for Health Research (NIHR) (NF-SI-0616-10011), NIHR Biomedical Research Centre (reference number 146281), and the Cure Parkinsons Trust. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp;  2020 Stoker TB and Barker RA. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Stoker TB and Barker RA. Recent developments in the treatment of Parkinson's Disease [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(Faculty Rev):862 (<a href="https://doi.org/10.12688/f1000research.25634.1" target=_blank>https://doi.org/10.12688/f1000research.25634.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 31 Jul 2020, <b>9</b>(Faculty Rev):862 (<a href="https://doi.org/10.12688/f1000research.25634.1" target=_blank>https://doi.org/10.12688/f1000research.25634.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 31 Jul 2020, <b>9</b>(Faculty Rev):862 (<a href="https://doi.org/10.12688/f1000research.25634.1" target=_blank>https://doi.org/10.12688/f1000research.25634.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d47403e160>Introduction</h2><p class="" id=d47403e163>Parkinsons disease (PD) is a common neurodegenerative disease characterised by a movement disorder consisting of bradykinesia, rest tremor, and rigidity, along with postural instability, a range of other more-subtle motor features, and many non-motor features<sup><a href="#ref-1">1</a></sup>. Many of the core motor features result from the loss of a specific population of neurons: the dopaminergic neurons of the substantia nigra pars compacta, which project axons to the striatum<sup><a href="#ref-2">2</a>,<a href="#ref-3">3</a></sup>. As such, most of the current pharmacological treatment approaches for PD aim to restore dopaminergic tone in the striatum.</p><p class="" id=d47403e177>Whilst often effective at improving motor function, current treatments are associated with significant side effects due to delivery of dopamine to extra-striatal regions, variability in their absorption and transit across the bloodbrain barrier, and the non-physiological continuous release of dopamine and its effects on the dopamine receptors within the basal ganglia<sup><a href="#ref-4">4</a>,<a href="#ref-5">5</a></sup>. Patients frequently develop cognitive problems, levodopa-induced dyskinesias, and on-off fluctuations, which we have estimated to occur in 46%, 56%, and 100% of cases, respectively, at 10 years from diagnosis based on data from our ongoing community-based incident study in PD<sup><a href="#ref-6">6</a>,<a href="#ref-7">7</a></sup>. All of these factors coupled with some of the neuropsychiatric features of PD have a significant impact on quality of life in advancing PD. Many features of PD (such as cognitive impairment and autonomic dysfunction) have a mainly non-dopaminergic basis, resulting from neurodegeneration at other sites in the central nervous system as well as the enteric and autonomic nervous systems<sup><a href="#ref-3">3</a>,<a href="#ref-8">8</a></sup>. It is often these features that have the most detrimental impact on the quality of life of patients with PD, yet treatment options remain limited for these elements of disease.</p><p class="" id=d47403e201>Levodopa, the precursor of dopamine, was first developed for the treatment of PD in the 1960s and continues to be the most-effective therapeutic agent for PD in 2020<sup><a href="#ref-9">9</a></sup>. Other dopaminergic drugs have since been used, including inhibitors of dopamine metabolism as well as dopamine receptor agonists, but these are generally less well tolerated and less effective. Thus, there is an urgent need for better therapies, including disease-modifying treatments. However, the requirement for relevant pre-clinical disease models for testing such agents and the lack of robust biomarkers for diagnosing PD and the identification of prodromal disease, which would allow for treatment before significant neuronal loss had occurred, pose barriers to drug discovery.</p><p class="" id=d47403e208>It is on this background that a number of new developments are emerging that may transform the management of PD over the coming years, and we will now discuss those that are in, or soon to be in, clinical trials (<a href="#f1">Figure 1</a>).</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/28292/57bd4120-790d-4cff-b25f-8702018a59da_figure1.gif"><img alt="57bd4120-790d-4cff-b25f-8702018a59da_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/28292/57bd4120-790d-4cff-b25f-8702018a59da_figure1.gif"></a><div class=caption><h3>Figure 1. Putative disease-modifying therapies for PD.</h3><p id=d47403e225>An expanding number of drugs are being considered for their ability to influence the pathogenic processes of PD. These include novel agents and technologies, such as active and passive immunisation and RNA interference techniques to limit the propagation, and synthesis, of -synuclein. Additionally, several drugs used for other conditions are of interest for potential use in PD given their ability to influence pathways such as the lysosomeautophagy system, mitochondrial function, and neuroinflammation, for example. Abbreviations: -syn, -synuclein; ASO, anti-sense oligonucleotide; GCase, glucocerebrosidase; PD, Parkinsons disease; RNA, ribonucleic acid; UDCA, ursodeoxycholic acid.</p></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d47403e235>Immunotherapies</h2><p class="" id=d47403e238>The pathological hallmark of PD is the presence of abnormal aggregates of -synuclein<sup><a href="#ref-10">10</a></sup>. The role of -synuclein in PD is not clear, but it is presumed to play a central pathogenic role, as demonstrated by the fact that mutations or duplications/triplications of the gene (<i>SNCA</i>) cause rare familial forms of PD<sup><a href="#ref-11">11</a></sup>, coupled with many independent studies showing the detrimental effects of manipulating -synuclein in cell and animal models<sup><a href="#ref-12">12</a>,<a href="#ref-13">13</a></sup>. Potential pathogenic mechanisms of -synuclein include dysfunction of vesicular transport, perturbations in the lysosomeautophagy system, mitochondrial dysfunction, and oxidative stress, for example<sup><a href="#ref-14">14</a></sup>. It has also been proposed that pathological forms of -synuclein can act in a prion-like fashion, allowing pathology to spread from cell to cell, and the strains underlying this are now being identified<sup><a href="#ref-15">15</a></sup>. This in turn means the disease follows a pattern of pathology that results from the sequential involvement of a number of anatomical structures. All of this suggests that therapies designed to reduce levels of -synuclein or the propagation of toxic strains may limit PD progression<sup><a href="#ref-8">8</a></sup>.</p><p class="" id=d47403e272>One experimental approach to restricting the propagation of -synuclein is to use antibodies to target and degrade extracellular -synuclein and thus prevent it from infecting neighbouring cells. Passive and active immunisation techniques against -synuclein have been shown to convey neuroprotective effects in animal models, with the results of early clinical trials in humans starting to emerge<sup><a href="#ref-14">14</a></sup>. Other approaches to reducing -synuclein levels include anti-sense oligonucleotide and ribonucleic acid (RNA) interference techniques to reduce its synthesis, though these remain in pre-clinical stages and are thus not discussed in detail here<sup><a href="#ref-16">16</a><a href="#ref-18">18</a></sup>.</p><p class="" id=d47403e286>A humanised monoclonal antibody targeting the C-terminus of aggregated -synuclein (prasinezumab or PRX002, Prothena) has been shown to reduce free serum -synuclein by approximately 97% and to be well tolerated in phase I clinical trials<sup><a href="#ref-19">19</a>,<a href="#ref-20">20</a></sup>, with a phase II trial currently underway (NCT03100149). Another antibody, BIIB054 (Biogen), targeting the N-terminal portion of -synuclein reduces the propagation of -synuclein pathology and improves the motor phenotype in a PD model involving injection of -synuclein pre-formed fibrils into mice<sup><a href="#ref-21">21</a></sup>. This antibody has also been found to be well tolerated in humans<sup><a href="#ref-22">22</a></sup> and is under investigation in a phase II clinical trial (NCT03318523).</p><p class="" id=d47403e304>The company AFFiRiS are approaching this problem in a different way by investigating a range of treatments consisting of -synuclein fragments or -synuclein-mimicking epitopes designed to induce an active immune response against -synuclein, with phase I trials completed (NCT01568099 and NCT02267434). These products have been administered subcutaneously in early trials and seem to be well tolerated. One of these, AFFITOPE PD01A, conveyed a dose-dependent immune response to the peptide itself and to -synuclein and is now being taken forward to phase II trials<sup><a href="#ref-14">14</a></sup>.</p><p class="" id=d47403e312>The use of immunotherapies to limit the propagation of PD pathology is an interesting avenue for further exploration, but important questions remain, not least the extent to which PD in the clinic is driven by protein spread. In addition, the ability of these antibodies to cross the bloodbrain barrier and influence -synuclein homeostasis in the brain is potentially an obstacle for their use in the clinic. Furthermore, neuroprotective effects of such immunotherapies appear in part to be due to intracellular effects, and their ability to enter cells may influence their efficacy. Engineered fragments (intrabodies and nanobodies) may allow for greater central nervous system penetration and entry to the cell, but these are yet to enter clinical trials<sup><a href="#ref-23">23</a></sup>. Another concern is the potential consequences of suppressing the physiological function of -synuclein, an abundant protein whose function is incompletely understood. Suppression of -synuclein levels in some models has been shown to be detrimental<sup><a href="#ref-24">24</a><a href="#ref-27">27</a></sup>, and evaluation of the long-term safety of this approach will be important. It is for this reason that some groups have sought to reduce -synuclein through drug therapies, including the repurposing of -agonists (see below).</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d47403e329>Drug repurposing</h2><p class="" id=d47403e332>An alternative approach to limit PD pathology and disease progression is through the use of drugs that reduce -synuclein pathology or have beneficial effects on other processes implicated in PD (<a href="#T1">Table 1</a>). In particular, there is a great deal of interest in drug repurposing (using established drugs for a new indication), which would potentially lead to an expedited path to the clinic, given that safety and pharmacokinetic data may already be available. Here we discuss some of the most promising agents being considered for the treatment of PD (<a href="#f1">Figure 1</a>).</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Clinical trials of putative disease-modifying treatments for Parkinsons disease.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d47403e352 class=n-a></a><thead><a name=d47403e354 class=n-a></a><tr><a name=d47403e356 class=n-a></a><th align=center colspan=1 rowspan=1 valign=top><a name=d47403e358 class=n-a></a>Drug/class</th><th align=center colspan=1 rowspan=1 valign=top><a name=d47403e361 class=n-a></a>Proposed mechanism</th><th align=center colspan=1 rowspan=1 valign=top><a name=d47403e364 class=n-a></a>Progress in trials</th></tr></thead><tbody><a name=d47403e369 class=n-a></a><tr><a name=d47403e371 class=n-a></a><th align=left colspan=3 rowspan=1 valign=top><a name=d47403e373 class=n-a></a>-synuclein reduction</th></tr><tr><a name=d47403e377 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e379 class=n-a></a>-agonists</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e382 class=n-a></a>Reduced -synuclein transcription through acetylation of<br class=br>promoters and enhancers of the <i>SNCA</i> gene<sup><a href="#ref-28">28</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e393 class=n-a></a>Not started</td></tr><tr><a name=d47403e397 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e399 class=n-a></a>Nilotinib</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e402 class=n-a></a>Inhibition of ABL tyrosine kinase activity and enhanced<br class=br>autophagy<sup><a href="#ref-34">34</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e410 class=n-a></a>Safe and tolerable but no clinical benefit in phase II<br class=br>trial</td></tr><tr><a name=d47403e416 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e418 class=n-a></a>Terazosin</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e421 class=n-a></a>Activation of PGK1 and HSP90, increased ATP levels, and<br class=br>reduced -synuclein levels<sup><a href="#ref-35">35</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e429 class=n-a></a>Single-centre randomised placebo-controlled trial<br class=br>currently enrolling patients</td></tr><tr><a name=d47403e435 class=n-a></a><th align=left colspan=3 rowspan=1 valign=top><a name=d47403e437 class=n-a></a>Mitochondrial function</th></tr><tr><a name=d47403e442 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e444 class=n-a></a>Ursodeoxycholic<br class=br>acid</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e449 class=n-a></a>Restoration of mitochondrial function</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e452 class=n-a></a>Randomised placebo-controlled trial currently<br class=br>recruiting patients</td></tr><tr><a name=d47403e458 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e460 class=n-a></a><i>N-</i>acetylcysteine</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e465 class=n-a></a>Antioxidant effect and elevation of glutathione levels<sup><a href="#ref-36">36</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e471 class=n-a></a>Small open-label phase II study showed no changes<br class=br>in indicators of oxidative damage or brain glutathione<br class=br>levels<sup><a href="#ref-36">36</a></sup></td></tr><tr><a name=d47403e482 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e484 class=n-a></a>Glutathione</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e487 class=n-a></a>Reduction in reactive oxygen species and free radical levels</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e490 class=n-a></a>Double-blind trial completed, with no clinical benefit<br class=br>demonstrated over placebo</td></tr><tr><a name=d47403e496 class=n-a></a><th align=left colspan=3 rowspan=1 valign=top><a name=d47403e498 class=n-a></a>Neuroinflammation</th></tr><tr><a name=d47403e502 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e504 class=n-a></a>Azathioprine</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e507 class=n-a></a>Modulation of peripheral immune system profile</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e510 class=n-a></a>Single-centre randomised placebo-controlled trial<br class=br>about to start enrolling patients</td></tr><tr><a name=d47403e516 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e518 class=n-a></a>Sargramostim<br class=br>(G-CSF)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e523 class=n-a></a>Induction of Treg immune responses<sup><a href="#ref-37">37</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e529 class=n-a></a>Phase I placebo-controlled trial completed<br class=br>Generally well tolerated, with reported modest<br class=br>improvement in UPDRS part III scores<sup><a href="#ref-38">38</a></sup></td></tr><tr><a name=d47403e541 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e543 class=n-a></a>AZD3241</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e546 class=n-a></a>Reduced oxidative stress and neuroinflammation through<br class=br>inhibition of myeloperoxidase</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e551 class=n-a></a>Phase 2a randomised placebo-controlled trial<br class=br>completed<br class=br>Safe and well tolerated with reduced nigrostriatal<br class=br>distribution of microglia<sup><a href="#ref-39">39</a></sup></td></tr><tr><a name=d47403e564 class=n-a></a><th align=left colspan=3 rowspan=1 valign=top><a name=d47403e566 class=n-a></a>Other</th></tr><tr><a name=d47403e570 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e572 class=n-a></a>Inosine</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e575 class=n-a></a>Elevation of urate levels</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e578 class=n-a></a>Randomised placebo-controlled phase III trial halted<br class=br>early in 2018, with results awaited</td></tr><tr><a name=d47403e584 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e586 class=n-a></a>Exenatide</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e589 class=n-a></a>GLP-1 receptor activation leading to inhibition of apoptosis,<br class=br>reduced microglial activation and neuroinflammation,<br class=br>reduced oxidative stress, and promotion of neurogenesis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e596 class=n-a></a>Well tolerated, with improvements seen in UPDRS part III<br class=br>scores in randomised controlled trial<sup><a href="#ref-40">40</a></sup><br class=br>Phase III trial currently in set-up</td></tr><tr><a name=d47403e607 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e609 class=n-a></a>Isradipine</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e612 class=n-a></a>Neuroprotection through blockade of L-type calcium<br class=br>channels in substantia nigra<sup><a href="#ref-41">41</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e620 class=n-a></a>Multicentre phase III trial recently completed, with no<br class=br>improvement in motor or quality of life outcomes</td></tr><tr><a name=d47403e626 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e628 class=n-a></a>Deferiprone</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e631 class=n-a></a>Iron chelation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e634 class=n-a></a>Phase II randomised double-blind placebo-controlled<br class=br>trial completed, demonstrating reduced iron content in<br class=br>caudate and dentate nucleus<br class=br>No significant clinical benefit<sup><a href="#ref-42">42</a></sup></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d47403e651 class=n-a></a><p id=d47403e653> Abbreviations: ATP, adenosine triphosphate; G-CSF, granulocyte colony-stimulating factor; GLP-1, glucagon-like peptide-1; HSP90, heat shock protein 90; PGK1, phosphoglycerate kinase-1; Treg, regulatory T cell; UPDRS, Unified Parkinsons Disease Rating Scale.</p></div></div></div><p class="" id=d47403e659>One class that is under consideration, but yet to enter clinical trials, is the -adrenergic receptor agonists, given recent epidemiological and <i>in vitro</i> work demonstrating an association with reduced -synuclein levels and risk of PD, thought to be mediated through modulation of <i>SNCA</i> transcription<sup><a href="#ref-28">28</a></sup>. Given that such agents are widely used in the treatment of reversible airway obstruction, and have been for many years, moving this to the clinic should be relatively straightforward.</p><p class="" id=d47403e672>Of those that have gone to clinical trials, the glucagon-like peptide-1 (GLP-1) analogue exenatide, which is used for the treatment of type two diabetes mellitus, has advanced the most. This agent has been trialled in PD patients after a similar compound (exendin-4) was found to convey neuroprotective effects in cell and animal models of nigral degeneration<sup><a href="#ref-29">29</a><a href="#ref-31">31</a></sup>. Several mechanisms have been proposed to mediate this effect through GLP-1 receptor activation, including inhibition of apoptosis, reduced microglial activation and neuroinflammation, reduced oxidative stress, and promotion of neurogenesis<sup><a href="#ref-32">32</a></sup>. In an initial open-label trial, exenatide was found to be safe in PD patients (though some experienced problems with weight loss), and there was an associated improvement in cognitive and motor function, which persisted after cessation of treatment<sup><a href="#ref-33">33</a></sup>. This was followed by a double-blind randomised placebo-controlled trial, which reported that once-weekly exenatide was associated with a reduction in Unified Parkinsons Disease Rating Scale (UPDRS) motor scores in comparison to the placebo group<sup><a href="#ref-40">40</a></sup>. A multicentre phase III trial is currently in set-up, in which participants will receive weekly exenatide or placebo (NCT04232969). A pegylated form of exenatide (NLY01), which harbours enhanced pharmacokinetic properties, has also recently been taken to a phase I trial in healthy volunteers, with results awaited (NCT03672604).</p><p class="" id=d47403e695>Another repurposed drug that has been trialled for PD is nilotinib. This is an ABL tyrosine kinase inhibitor used in the treatment of chronic myelogenous leukaemia. ABL activity inhibits the activity of Parkin, which is important in the initiation of mitophagy, and nilotinib is proposed to enhance autophagy activity, potentially reducing the accumulation of -synuclein aggregates<sup><a href="#ref-34">34</a></sup>. An initial phase I trial reported that the drug was well tolerated and safe, with preliminary reports of benefits on motor and cognitive function<sup><a href="#ref-43">43</a></sup>. However, there was no placebo group in this study, and some of the clinical effects observed may have been due to baseline differences between the groups and withdrawal of monoamine oxidase inhibitors in a number of subjects<sup><a href="#ref-44">44</a></sup>. Nevertheless, nilotinib has now progressed to randomised placebo-controlled trials (NCT03205488 and NCT02954978), and it appears to reduce the ratio of pathogenic oligomeric -synuclein to total -synuclein in the cerebrospinal fluid (CSF)<sup><a href="#ref-45">45</a></sup>. However, a recent press release for the NILO-PD trial showed that, while safe and tolerable, nilotinib did not offer any clinical benefit.</p><p class="" id=d47403e714>Terazosin, an <sub>1</sub>-adrenergic antagonist used in benign prostatic hypertrophy, has recently emerged as a putative treatment for PD. Terazosin has been found to activate phosphoglycerate kinase-1 and the chaperone protein HSP90, which is involved in multiple intracellular stress responses<sup><a href="#ref-46">46</a></sup>. It has been shown to have neuroprotective effects in neurotoxin models of nigrostriatal degeneration in invertebrates and rodents, including after delayed administration<sup><a href="#ref-35">35</a></sup>. Additionally, terazosin reduced -synuclein levels in transgenic mice and in neurons derived from patients with <i>LRRK2</i> mutation-associated PD<sup><a href="#ref-35">35</a></sup>. Furthermore, a retrospective epidemiological study found that people taking terazosin have a reduced relative risk of PD<sup><a href="#ref-35">35</a></sup>. These promising findings have led to terazosin rapidly progressing to a randomised placebo-controlled trial, which will involve 20 patients with Hoehn and Yahr stage 3 PD (NCT03905811). However, terazosin reduces blood pressure and can cause orthostatic hypotension, which is a problem in many patients with advancing PD and may limit its applicability in this disease.</p><p class="" id=d47403e740>In addition to targeting -synuclein clearance pathways, drugs that target other intracellular pathways may be useful in PD. For example, ursodeoxycholic acid (UCDA), a drug used to treat primary biliary cirrhosis, has been found to restore mitochondrial function in cells derived from patients carrying <i>PARKIN</i> and <i>LRRK2</i> mutations as well as in invertebrate and rodent models of PD<sup><a href="#ref-47">47</a><a href="#ref-49">49</a></sup>. UCDA has recently progressed to a randomised placebo-controlled phase II trial, which is currently in the process of recruiting 30 patients with early PD (NCT03840005). A number of other agents are currently in, or have recently completed, clinical trials, which are summarised in <a href="#T1">Table 1</a>.</p><p class="" id=d47403e759>Advances in our understanding of pathogenic subtypes of PD may allow for the targeting of specific pathogenic mechanisms in subgroups of PD patients. One such group is patients carrying <i>GBA1</i> mutations, found in approximately 5% of so-called sporadic PD patients<sup><a href="#ref-50">50</a><a href="#ref-52">52</a></sup>. The <i>GBA1</i> gene encodes the lysosomal enzyme glucocerebrosidase, the activity of which has been found to be reduced in PD patients without <i>GBA1</i> mutations, making it an interesting therapeutic target for a wider PD population. These mutations are associated with dysfunction of the lysosomeautophagy system, important in -synuclein clearance<sup><a href="#ref-53">53</a>,<a href="#ref-54">54</a></sup>. Some <i>GBA1</i> mutations have been shown to lead to misfolding of glucocerebrosidase, which impairs its delivery to the lysosomal compartment, leading to perturbations in -synuclein processing<sup><a href="#ref-54">54</a></sup>. Ambroxol, historically used as an expectorant, has recently been trialled in patients with <i>GBA1</i> mutation-associated PD, as it has been shown to facilitate the re-folding of glucocerebrosidase and increase its activity in human cells and transgenic mice with subsequent reduction in -synuclein levels<sup><a href="#ref-55">55</a>,<a href="#ref-56">56</a></sup>. The results of the first open-label clinical trial of ambroxol in PD patients with and without <i>GBA1</i> mutations (AiM-PD) have recently been published, where the drug was found to be well tolerated over 6 months, with an associated rise in CSF glucocerebrosidase levels<sup><a href="#ref-57">57</a></sup>.</p><p class="" id=d47403e810>Alternatively, the glucocerebrosidase pathway may be targeted through glucosylceramide synthase inhibitors, which reduce levels of the glucocerebrosidase substrates glucosylceramide and glucosylsphingosine. Such substrate reduction therapies have been used in Gaucher disease (caused by biallelic mutations in the <i>GBA1</i> gene), but the role of these substrates in PD pathogenesis is disputed<sup><a href="#ref-58">58</a></sup>. A phase II clinical trial of a glucosylceramide synthase inhibitor (venglustat) in PD patients with <i>GBA1</i> variants is currently underway (MOVES-PD, NCT02906020).</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d47403e826>Targeting non-dopaminergic neurotransmitter systems</h2><p class="" id=d47403e829>Though many of the motor features of PD are dopamine responsive, for others, such as freezing of gait and tremor, dopamine offers little benefit. It is now understood that deficiencies in other neurotransmitter systems underlie some of these features<sup><a href="#ref-59">59</a></sup>. As such, there is interest in modulating their function to treat specific dopamine-resistant aspects of PD.</p><p class="" id=d47403e836>One novel drug that has recently received approval for use in PD is safinamide, a drug that is proposed to have multi-modal actions. It is a potent reversible monoamine oxidase B inhibitor, conveying a benefit for the treatment of dopaminergic aspects of PD. It also modulates glutamate transmission, which may be implicated in some of the non-motor features of PD<sup><a href="#ref-60">60</a>,<a href="#ref-61">61</a></sup>. In a multicentre phase III clinical trial involving 669 patients with moderate to advanced PD, safinamide resulted in improved UPDRS motor scores, reduced off-time, and improvements in depression and communication scores<sup><a href="#ref-62">62</a></sup>. Safinamide is now becoming more widely available for clinical use, though its exact role is yet to be determined. Currently, it is most likely to be used as an adjunct to levodopa-based therapies, particularly in those who experience problematic dyskinesias and fluctuations.</p><p class="" id=d47403e850>Additionally, the cholinesterase inhibitors rivastigmine and donepezil have been trialled for their ability to reduce falls in PD, with promising preliminary results<sup><a href="#ref-63">63</a>,<a href="#ref-64">64</a></sup>. The noradrenaline reuptake inhibitors methylphenidate and atomoxetine are also currently being investigated for their effects on balance and gait in PD in an ongoing trial (NCT02879136). Serotoninergic neurons in the dorsal raphe nucleus have been proposed to contribute to levodopa-induced dyskinesias, and the use of serotonin agonists has been seen to reduce such dyskinesias in animal models<sup><a href="#ref-65">65</a><a href="#ref-67">67</a></sup>. However, their use has been accompanied by worsening of other motor features of PD in some clinical studies<sup><a href="#ref-68">68</a></sup>. However, advances in our understanding of the role of the serotoninergic system in the development of levodopa-induced dyskinesias means that there is ongoing interest in modulation of this system as a therapeutic option<sup><a href="#ref-69">69</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d47403e878>Neurotrophic factors</h2><p class="" id=d47403e881>Neurotrophic factors such as glial cell line-derived neurotrophic factor (GDNF) have beneficial effects on dopaminergic neurons in pre-clinical models, and there has been much interest in developing neuroprotective therapies based on these<sup><a href="#ref-70">70</a>,<a href="#ref-71">71</a></sup>.</p><p class="" id=d47403e891>Open-label studies of intraputaminal GDNF infusion have seen improvements in motor UPDRS scores<sup><a href="#ref-72">72</a>,<a href="#ref-73">73</a></sup>, with some evidence of restoration of the nigrostriatal pathway pathologically and on imaging<sup><a href="#ref-74">74</a></sup>. However, randomised double-blind trials have failed to recapitulate these results, including a recent study in the UK<sup><a href="#ref-75">75</a>,<a href="#ref-76">76</a></sup>. However, there has been much discussion about why these open and double-blind studies have produced such varying results, which led to a workshop in 2019 where these issues were addressed; the conclusions of which have recently been published<sup><a href="#ref-77">77</a></sup>. Whilst GDNF studies have thus far yielded mixed results, this remains an exciting experimental approach with ongoing interest. Variable results in these trials may in part be due to the involvement of patients with moderately advanced PD, inadequate follow-up times, and the large placebo effect (which is often seen in clinical trials for PD).</p><p class="" id=d47403e916>Neurturin, a GDNF analogue, has also been trialled in patients, with similar results to those seen with GDNF, namely promising open-label trials that have failed to translate to clinical benefit in larger trials<sup><a href="#ref-78">78</a><a href="#ref-81">81</a></sup>. Nevertheless, determination of the most-appropriate patients, improvement in delivery systems, and development of novel neurotrophic factor analogues mean that this approach remains an avenue of interest and is currently being explored in a new EU-funded trial looking at cerebral dopamine neurotrophic factor (CDNF, Herantis Pharma). It has recently been reported in a press release that the agent can be delivered without major side effects, although it is too early to say whether it has therapeutic benefits for patients.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d47403e930>Regenerative treatments</h2><p class="" id=d47403e933>As well as the pharmacological approaches described above, there is considerable interest in the use of cell-based and gene therapies to replace the function of the lost dopaminergic neurons. The aim of these treatments is to restore dopaminergic tone in a more targeted and physiological manner than can be achieved with current dopaminergic therapies. Several of these approaches are now entering clinical trials<sup><a href="#ref-82">82</a></sup>.</p><p class="" id=d47403e940>Gene therapies may be used to increase dopamine levels in the striatum through the introduction of genes that mediate dopamine synthesis. Tyrosine hydroxylase (TH) is needed for the production of the dopamine precursor levodopa, which in turn is converted to dopamine by DOPA decarboxylase, also termed aromatic L-amino acid decarboxylase (AADC). Two gene therapies involving the genes encoding these enzymes are currently undergoing clinical trials for PD.</p><p class="" id=d47403e943>Voyager Therapeutics have developed an adeno-associated virus (AAV) therapy containing the gene for AADC (VY-AADC). This therapy has entered a phase I clinical trial, in which 15 patients with advanced PD are receiving the treatment at three different doses. It is introduced into the putamen, with preliminary reports suggesting that the treatment is well tolerated. The effects seem encouraging, particularly given that the volume of agent delivered covers a large part of the target structure (the putamen), with corresponding increases in enzyme activity. These benefits correlated with a dose-dependent reduction in levodopa dose<sup><a href="#ref-83">83</a></sup>. A randomised sham-surgery controlled phase II trial is also ongoing (NCT03562494).</p><p class="" id=d47403e950>A tricistronic lentivirus vector is also currently undergoing clinical trials. This treatment consists of the genes encoding AADC, TH, and GTP cyclohydrolase 1 (which catalyses the rate-limiting step of tetrahydrobiopterin synthesis, a cofactor required for the synthesis of dopamine and serotonin). The first iteration of this treatment to enter trials, OXB-101 or ProSavin, was assessed in an open-label phase I trial involving 15 patients with advanced PD<sup><a href="#ref-84">84</a></sup>. The treatment was well tolerated, with no serious adverse effects related to the treatment, with improvements in off state UPDRS scores at 12 months. However, the extent of improvement was not sufficient to make this therapy competitive. However, an improved version of this gene therapy with greater potency, OXB-102 or AXO-Lenti-PD, is currently in a two-part clinical trial in which safety will be assessed at multiple doses before progression to a randomised double-blind trial (NCT03720418).</p><p class="" id=d47403e958>Cell-based therapies offer another emerging approach for the targeted replacement of dopamine to treat the dopamine-dependent aspects of PD. Cell-grafting with human foetal ventral mesencephalon has been taking place since the 1980s, and whilst this has been seen to be effective in some cases with patients able to come off dopaminergic medication for sustained periods, it has become clear that logistical barriers regarding the supply of adequate tissue will prevent this from ever being a useful treatment in itself<sup><a href="#ref-85">85</a><a href="#ref-88">88</a></sup>. Nevertheless, a renewable source of dopaminergic cells would make cell-based therapies potentially feasible, assuming they can be shown to have sustained clinical benefits to patients.</p><p class="" id=d47403e968>Stem cells offer a renewable source of dopaminergic neuron progenitor cells that can be grafted into patients, and clinical trials of such products are now underway (<a href="#T2">Table 2</a>). Whilst controversial trials involving parthenogenetic stem cell-derived neural stem cells have been ongoing for several years<sup><a href="#ref-89">89</a></sup>, new stem cell products developed on the back of robust pre-clinical data are now progressing to trials<sup><a href="#ref-82">82</a></sup>. A clinical trial of dopaminergic progenitors derived from induced pluripotent stem cells (iPSCs) has begun (Center for iPS Cell Research and Application, Kyoto University, Japan). In this trial, seven patients will receive bilateral grafts of allogenic iPSC-derived cells. Trials involving embryonic stem cell (ESC)-derived cells are underway in China (NCT03119636)<sup><a href="#ref-90">90</a></sup> and in set-up in the USA (NYSTEM-PD) and the UK/Sweden (STEM-PD trial). A number of other trials using ESC-derived neurons and allogenic and autologous iPSC-derived neurons are expected to commence over the next 2 to 3 years.</p><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Current and planned trials of human stem cell-derived neuronal products.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d47403e997 class=n-a></a><thead><a name=d47403e999 class=n-a></a><tr><a name=d47403e1001 class=n-a></a><th align=center colspan=1 rowspan=1 valign=top><a name=d47403e1002 class=n-a></a>Trial</th><th align=center colspan=1 rowspan=1 valign=top><a name=d47403e1005 class=n-a></a>Country</th><th align=center colspan=1 rowspan=1 valign=top><a name=d47403e1008 class=n-a></a>Cell source</th><th align=center colspan=1 rowspan=1 valign=top><a name=d47403e1011 class=n-a></a>Number of<br class=br>patients</th><th align=center colspan=1 rowspan=1 valign=top><a name=d47403e1016 class=n-a></a>Status</th></tr></thead><tbody><a name=d47403e1021 class=n-a></a><tr><a name=d47403e1023 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1025 class=n-a></a>Center for iPS Cell Research<br class=br>and Application</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1030 class=n-a></a>Japan</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1033 class=n-a></a>Allogenic iPSCs</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1036 class=n-a></a>7</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1039 class=n-a></a>Started</td></tr><tr><a name=d47403e1043 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1045 class=n-a></a>NYSTEM-PD</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1048 class=n-a></a>USA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1051 class=n-a></a>ESCs (H9 cell line)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1054 class=n-a></a>10</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1057 class=n-a></a>Pending decision<br class=br>from FDA</td></tr><tr><a name=d47403e1063 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1065 class=n-a></a>Chinese Academy of Sciences</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1068 class=n-a></a>China</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1071 class=n-a></a>ESCs</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1074 class=n-a></a>50</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1077 class=n-a></a>Ongoing</td></tr><tr><a name=d47403e1081 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1083 class=n-a></a>European STEM-PD trial</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1086 class=n-a></a>UK and<br class=br>Sweden</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1091 class=n-a></a>ESCs (RC17 cell line)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1094 class=n-a></a>To be confirmed</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1097 class=n-a></a>In set-up</td></tr><tr><a name=d47403e1101 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1103 class=n-a></a>Fujifilm cellular dynamics<br class=br>international</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1108 class=n-a></a>USA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1111 class=n-a></a>Autologous iPSCs</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1114 class=n-a></a>To be confirmed</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1117 class=n-a></a>In set-up</td></tr><tr><a name=d47403e1122 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1124 class=n-a></a>Allife Medical Science and<br class=br>Technology Co., Ltd.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1129 class=n-a></a>China</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1132 class=n-a></a>Autologous iPS-neural stem<br class=br>cells</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1137 class=n-a></a>10</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1140 class=n-a></a>In set-up</td></tr><tr><a name=d47403e1144 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1146 class=n-a></a>Aspen Neuroscience</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1149 class=n-a></a>USA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1152 class=n-a></a>Autologous iPSCs</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1155 class=n-a></a>To be confirmed</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1158 class=n-a></a>In development</td></tr><tr><a name=d47403e1162 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1164 class=n-a></a>International Stem Cell<br class=br>Corporation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1169 class=n-a></a>Australia</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1172 class=n-a></a>Parthenogenetic ESC-derived<br class=br>neural stem cells</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1177 class=n-a></a>12</td><td align=left colspan=1 rowspan=1 valign=top><a name=d47403e1180 class=n-a></a>Ongoing</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d47403e1188 class=n-a></a><p id=d47403e1190> Abbreviations: ESC, embryonic stem cell; FDA, US Food and Drug Administration; iPSC, induced pluripotent stem cell.</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d47403e1199>Advances in deep brain stimulation</h2><p class="" id=d47403e1202>Deep brain stimulation (DBS) is another established treatment for PD that is useful in treating dopamine-dependent motor symptoms when levodopa-induced side effects become particularly problematic. DBS involves the surgical implantation of electrodes that stimulate subcortical structures including the subthalamic nucleus and globus pallidus internus<sup><a href="#ref-91">91</a><a href="#ref-94">94</a></sup>. DBS offers significant improvements in motor symptoms and fluctuations in comparison to best medical therapy in some advanced PD patients, but dopamine-resistant symptoms other than tremor (e.g. gait disturbance and postural instability) respond poorly<sup><a href="#ref-95">95</a></sup>. It has also been suggested in an open-label trial that DBS is beneficial in early PD patients, with improved tremor scores and reduced development of <i>de novo</i> tremor<sup><a href="#ref-96">96</a></sup>. In addition to surgical complications, DBS strategies may cause cognitive and neuropsychiatric adverse effects as well as speech dysfunction. Novel DBS approaches, including adaptive DBS, targeting different regions, and refined intra-operative imaging techniques promise to offer improved clinical applicability and reduce the impact of adverse effects<sup><a href="#ref-97">97</a></sup>.</p><p class="" id=d47403e1227>The pedunculopontine nucleus has recently been trialled as a new target for DBS, particularly for the gait problems seen in PD. While initial trials reported positive impacts on gait and postural instability, more rigorous subsequent trials were less promising, in part because of variability in the anatomical definition of the pedunculopontine nucleus in the human brain, suboptimal programming settings, and low patient numbers<sup><a href="#ref-61">61</a>,<a href="#ref-98">98</a></sup>. More recently, stimulation of the substantia nigra reticularis has shown promising effects on axial symptoms in preliminary studies<sup><a href="#ref-99">99</a></sup> along with stimulation of the basal forebrain (with STN) for some of the cognitive deficits in PD<sup><a href="#ref-100">100</a></sup>. In another pilot study, thoracic spinal cord stimulation significantly reduced the frequency of freezing episodes in patients with advanced PD, with trials ongoing<sup><a href="#ref-101">101</a></sup>.</p><p class="" id=d47403e1249>There is great interest in adaptive DBS, a system in which the stimulation delivered to the target is adjusted in response to physiological signals<sup><a href="#ref-61">61</a></sup>. This approach theoretically limits adverse effects, improves clinical response, and reduces the requirements for battery changes and the associated cost. Further work is required in identifying and validating a reliable host signal<sup><a href="#ref-102">102</a></sup>, but it is hoped that such technologies will enhance the clinical utility of DBS in the future. Non-invasive DBS techniques involving the use of external devices delivering electric fields to deep structures would circumvent the need for neurosurgery and its associated risks<sup><a href="#ref-103">103</a></sup>. One such approach that has been used more for patients with essential tremor than PD involves using magnetic resonance imaging-focussed ultrasound lesioning of discrete brain structures. Reports on the long-term efficacy of these therapies are awaited<sup><a href="#ref-104">104</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d47403e1271>Conclusion</h2><p class="" id=d47403e1274>A wide variety of experimental treatment approaches for PD have progressed towards the clinic over recent years. Many previous putative treatments have fallen by the wayside when taken to clinical trials, despite being backed up by promising pre-clinical results, emphasising the need for robust trial design. A greater understanding of the pathogenic mechanisms and anatomical basis for PD symptoms has opened up avenues for new treatment modalities, and it now seems probable that the management of PD will evolve significantly over the coming years.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d47403e1281 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class=faculty-opinion-icon></span><span class="prime-red big">Faculty Opinions recommended</span></span><h2 class=main-title id=d48097>References</h2><div class="section ref-list"><a name=d47403e1281 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d47403e1288 class=n-a></a>Kalia LV, Lang AE: Parkinson's disease. <i>Lancet.</i> 2015; <b>386</b>(9996): 896912. <a target=xrefwindow id=d47403e1296 href="http://www.ncbi.nlm.nih.gov/pubmed/25904081">PubMed Abstract </a> | <a target=xrefwindow id=d47403e1299 href="https://doi.org/10.1016/S0140-6736(14)61393-3">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d47403e1308 class=n-a></a>Dickson DW: Parkinson's disease and parkinsonism: Neuropathology. <i>Cold Spring Harb Perspect Med.</i> 2012; <b>2</b>(8): a009258. <a target=xrefwindow id=d47403e1316 href="http://www.ncbi.nlm.nih.gov/pubmed/22908195">PubMed Abstract </a> | <a target=xrefwindow id=d47403e1319 href="https://doi.org/10.1101/cshperspect.a009258">Publisher Full Text </a> | <a target=xrefwindow id=d47403e1322 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3405828">Free Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/1165827"><span class="faculty-opinion-icon small"></span></a><a name=d47403e1331 class=n-a></a>Selikhova M, Williams DR, Kempster PA, <i> et al.</i>: A clinico-pathological study of subtypes in Parkinson's disease. <i>Brain.</i> 2009; <b>132</b>(Pt 11): 294757. <a target=xrefwindow id=d47403e1342 href="http://www.ncbi.nlm.nih.gov/pubmed/19759203">PubMed Abstract </a> | <a target=xrefwindow id=d47403e1345 href="https://doi.org/10.1093/brain/awp234">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/1165827">Faculty Opinions Recommendation</a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d47403e1358 class=n-a></a>Huot P, Johnston TH, Koprich JB, <i> et al.</i>: The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease. <i>Pharmacol Rev.</i> 2013; <b>65</b>(1): 171222. <a target=xrefwindow id=d47403e1369 href="http://www.ncbi.nlm.nih.gov/pubmed/23319549">PubMed Abstract </a> | <a target=xrefwindow id=d47403e1372 href="https://doi.org/10.1124/pr.111.005678">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d47403e1381 class=n-a></a>Jenner P: Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease. <i>Curr Opin Neurol.</i> 2003; <b>16 Suppl 1</b>: S3S7. <a target=xrefwindow id=d47403e1389 href="http://www.ncbi.nlm.nih.gov/pubmed/15180131">PubMed Abstract </a> | <a target=xrefwindow id=d47403e1392 href="https://doi.org/10.1097/00019052-200312001-00002">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d47403e1402 class=n-a></a>Williams-Gray CH, Mason SL, Evans JR, <i> et al.</i>: The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. <i>J Neurol Neurosurg Psychiatr.</i> 2013; <b>84</b>(11): 125864. <a target=xrefwindow id=d47403e1413 href="http://www.ncbi.nlm.nih.gov/pubmed/23781007">PubMed Abstract </a> | <a target=xrefwindow id=d47403e1416 href="https://doi.org/10.1136/jnnp-2013-305277">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d47403e1425 class=n-a></a>Kim HJ, Mason S, Foltynie T, <i> et al.</i>: Motor complications in Parkinson's disease: 13-year follow-up of the CamPaIGN cohort. <i>Mov Disord.</i> 2020; <b>35</b>(1): 18590. <a target=xrefwindow id=d47403e1436 href="http://www.ncbi.nlm.nih.gov/pubmed/31965629">PubMed Abstract </a> | <a target=xrefwindow id=d47403e1439 href="https://doi.org/ 10.1002/mds.27882">Publisher Full Text </a> | <a target=xrefwindow id=d47403e1443 href="http://www.ncbi.nlm.nih.gov/pmc/articles/7063985">Free Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d47403e1452 class=n-a></a>Braak H, Tredici KD, Rb U, <i> et al.</i>: Staging of brain pathology related to sporadic Parkinsons disease. <i>Neurobiol Aging.</i> 2003; <b>24</b>(2): 197211. <a target=xrefwindow id=d47403e1463 href="http://www.ncbi.nlm.nih.gov/pubmed/12498954">PubMed Abstract </a> | <a target=xrefwindow id=d47403e1466 href="https://doi.org/10.1016/s0197-4580(02)00065-9">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d47403e1475 class=n-a></a>Cotzias GC, van Woert MH, Schiffer LM: Aromatic amino acids and modification of parkinsonism. <i>N Engl J Med.</i> 1967; <b>276</b>(7): 3749. <a target=xrefwindow id=d47403e1483 href="http://www.ncbi.nlm.nih.gov/pubmed/5334614">PubMed Abstract </a> | <a target=xrefwindow id=d47403e1486 href="https://doi.org/10.1056/NEJM196702162760703">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d47403e1495 class=n-a></a>Spillantini MG, Schmidt ML, Lee VM, <i> et al.</i>: Alpha-Synuclein in Lewy bodies. <i>Nature.</i> 1997; <b>388</b>(6645): 83940. <a target=xrefwindow id=d47403e1506 href="http://www.ncbi.nlm.nih.gov/pubmed/9278044">PubMed Abstract </a> | <a target=xrefwindow id=d47403e1509 href="https://doi.org/10.1038/42166">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d47403e1518 class=n-a></a>Polymeropoulos MH, Lavedan C, Leroy E, <i> et al.</i>: Mutation in the -Synuclein Gene Identified in Families with Parkinson's Disease. <i>Science.</i> 1997; <b>276</b>(5321): 20457. <a target=xrefwindow id=d47403e1529 href="http://www.ncbi.nlm.nih.gov/pubmed/9197268">PubMed Abstract </a> | <a target=xrefwindow id=d47403e1532 href="https://doi.org/10.1126/science.276.5321.2045">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/717963993"><span class="faculty-opinion-icon small"></span></a><a name=d47403e1542 class=n-a></a>Luk KC, Kehm V, Carroll J, <i> et al.</i>: Pathological -Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice. <i>Science.</i> 2012; <b>338</b>(6109): 94953. <a target=xrefwindow id=d47403e1553 href="http://www.ncbi.nlm.nih.gov/pubmed/23161999">PubMed Abstract </a> | <a target=xrefwindow id=d47403e1556 href="https://doi.org/10.1126/science.1227157">Publisher Full Text </a> | <a target=xrefwindow id=d47403e1560 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3552321">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/717963993">Faculty Opinions Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d47403e1573 class=n-a></a>Giasson BI, Duda JE, Quinn SM, <i> et al.</i>: Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein in pubmed. <i>Neuron.</i> 2002; <b>34</b>(4): 52133. <a target=xrefwindow id=d47403e1584 href="http://www.ncbi.nlm.nih.gov/pubmed/12062037">PubMed Abstract </a> | <a target=xrefwindow id=d47403e1587 href="https://doi.org/10.1016/s0896-6273(02)00682-7">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/737125652"><span class="faculty-opinion-icon small"></span></a><a name=d47403e1596 class=n-a></a>Fields CR, Bengoa-Vergniory N, Wade-Martins R: Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease. <i>Front Mol Neurosci.</i> 2019; <b>12</b>: 299. <a target=xrefwindow id=d47403e1604 href="http://www.ncbi.nlm.nih.gov/pubmed/31866823">PubMed Abstract </a> | <a target=xrefwindow id=d47403e1607 href="https://doi.org/10.3389/fnmol.2019.00299">Publisher Full Text </a> | <a target=xrefwindow id=d47403e1610 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6906193">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/737125652">Faculty Opinions Recommendation</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/737326195"><span class="faculty-opinion-icon small"></span></a><a name=d47403e1623 class=n-a></a>Shahnawaz M, Mukherjee A, Pritzkow S, <i> et al.</i>: Discriminating -synuclein strains in Parkinsons disease and multiple system atrophy. <i>Nature.</i> 2020; <b>578</b>(7794): 2737. <a target=xrefwindow id=d47403e1634 href="http://www.ncbi.nlm.nih.gov/pubmed/32025029">PubMed Abstract </a> | <a target=xrefwindow id=d47403e1637 href="https://doi.org/10.1038/s41586-020-1984-7">Publisher Full Text </a> | <a target=xrefwindow id=d47403e1641 href="http://www.ncbi.nlm.nih.gov/pmc/articles/7066875">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/737326195">Faculty Opinions Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d47403e1654 class=n-a></a>Sapru MK, Yates JW, Hogan S, <i> et al.</i>: Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. <i>Exp Neurol.</i> 2006; <b>198</b>(2): 38290. <a target=xrefwindow id=d47403e1665 href="http://www.ncbi.nlm.nih.gov/pubmed/16455076">PubMed Abstract </a> | <a target=xrefwindow id=d47403e1668 href="https://doi.org/10.1016/j.expneurol.2005.12.024">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d47403e1677 class=n-a></a>Lewis J, Melrose H, Bumcrot D, <i> et al.</i>: <i>In vivo</i> silencing of alpha-synuclein using naked siRNA. <i>Mol Neurodegener.</i> 2008; <b>3</b>: 19. <a target=xrefwindow id=d47403e1691 href="http://www.ncbi.nlm.nih.gov/pubmed/18976489">PubMed Abstract </a> | <a target=xrefwindow id=d47403e1695 href="https://doi.org/10.1186/1750-1326-3-19">Publisher Full Text </a> | <a target=xrefwindow id=d47403e1698 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2612658">Free Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d47403e1708 class=n-a></a>McCormack AL, Mak SK, Henderson JM, <i> et al.</i>: Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. <i>PLoS One.</i> 2010; <b>5</b>(8): e12122. <a target=xrefwindow id=d47403e1719 href="http://www.ncbi.nlm.nih.gov/pubmed/20711464">PubMed Abstract </a> | <a target=xrefwindow id=d47403e1722 href="https://doi.org/10.1371/journal.pone.0012122">Publisher Full Text </a> | <a target=xrefwindow id=d47403e1726 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2920329">Free Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d47403e1735 class=n-a></a>Schenk DB, Koller M, Ness DK, <i> et al.</i>: First-in-human assessment of PRX002, an anti--synuclein monoclonal antibody, in healthy volunteers. <i>Mov Disord.</i> 2017; <b>32</b>(2): 2118. <a target=xrefwindow id=d47403e1746 href="http://www.ncbi.nlm.nih.gov/pubmed/27886407">PubMed Abstract </a> | <a target=xrefwindow id=d47403e1749 href="https://doi.org/10.1002/mds.26878">Publisher Full Text </a> | <a target=xrefwindow id=d47403e1753 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5324684">Free Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/733466919"><span class="faculty-opinion-icon small"></span></a><a name=d47403e1762 class=n-a></a>Jankovic J, Goodman I, Safirstein B, <i> et al.</i>: Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti--Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. <i>JAMA Neurol.</i> 2018; <b>75</b>(10): 120614. <a target=xrefwindow id=d47403e1773 href="http://www.ncbi.nlm.nih.gov/pubmed/29913017">PubMed Abstract </a> | <a target=xrefwindow id=d47403e1776 href="https://doi.org/10.1001/jamaneurol.2018.1487">Publisher Full Text </a> | <a target=xrefwindow id=d47403e1780 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6233845">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/733466919">Faculty Opinions Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/734350604"><span class="faculty-opinion-icon small"></span></a><a name=d47403e1793 class=n-a></a>Weihofen A, Liu Y, Arndt JW, <i> et al.</i>: Development of an aggregate-selective, human-derived -synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models. <i>Neurobiol Dis.</i> 2019; <b>124</b>: 27688. <a target=xrefwindow id=d47403e1804 href="http://www.ncbi.nlm.nih.gov/pubmed/30381260">PubMed Abstract </a> | <a target=xrefwindow id=d47403e1807 href="https://doi.org/10.1016/j.nbd.2018.10.016">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/734350604">Faculty Opinions Recommendation</a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/736011651"><span class="faculty-opinion-icon small"></span></a><a name=d47403e1820 class=n-a></a>Brys M, Fanning L, Hung S, <i> et al.</i>: Randomized phase I clinical trial of anti-synuclein antibody BIIB054. <i>Mov Disord.</i> 2019; <b>34</b>(8): 115463. <a target=xrefwindow id=d47403e1831 href="http://www.ncbi.nlm.nih.gov/pubmed/31211448">PubMed Abstract </a> | <a target=xrefwindow id=d47403e1834 href="https://doi.org/10.1002/mds.27738">Publisher Full Text </a> | <a target=xrefwindow id=d47403e1838 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6771554">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/736011651">Faculty Opinions Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d47403e1851 class=n-a></a>Zhou C, Emadi S, Sierks MR, <i> et al.</i>: A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. <i>Mol Ther.</i> 2004; <b>10</b>(6): 102331. <a target=xrefwindow id=d47403e1862 href="http://www.ncbi.nlm.nih.gov/pubmed/15564134">PubMed Abstract </a> | <a target=xrefwindow id=d47403e1865 href="https://doi.org/10.1016/j.ymthe.2004.08.019">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d47403e1875 class=n-a></a>Robertson DC, Schmidt O, Ninkina N, <i> et al.</i>: Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice. <i>J Neurochem.</i> 2004; <b>89</b>(5): 112636. <a target=xrefwindow id=d47403e1886 href="http://www.ncbi.nlm.nih.gov/pubmed/15147505">PubMed Abstract </a> | <a target=xrefwindow id=d47403e1889 href="https://doi.org/10.1111/j.1471-4159.2004.02378.x">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d47403e1898 class=n-a></a>Kanaan NM, Manfredsson FP: Loss of Functional Alpha-Synuclein: A Toxic Event in Parkinson's Disease? <i>J Parkinsons Dis.</i> 2012; <b>2</b>(4): 24967. <a target=xrefwindow id=d47403e1906 href="http://www.ncbi.nlm.nih.gov/pubmed/23938255">PubMed Abstract </a> | <a target=xrefwindow id=d47403e1909 href="https://doi.org/10.3233/JPD-012138">Publisher Full Text </a> | <a target=xrefwindow id=d47403e1912 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4736738">Free Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d47403e1921 class=n-a></a>Gorbatyuk OS, Li S, Nash K, <i> et al.</i>: <i>In Vivo</i> RNAi-Mediated -Synuclein Silencing Induces Nigrostriatal Degeneration. <i>Mol Ther.</i> 2010; <b>18</b>(8): 14507. <a target=xrefwindow id=d47403e1935 href="http://www.ncbi.nlm.nih.gov/pubmed/20551914">PubMed Abstract </a> | <a target=xrefwindow id=d47403e1939 href="https://doi.org/10.1038/mt.2010.115">Publisher Full Text </a> | <a target=xrefwindow id=d47403e1942 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2927065">Free Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/732787291"><span class="faculty-opinion-icon small"></span></a><a name=d47403e1951 class=n-a></a>Benskey MJ, Sellnow RC, Sandoval IM, <i> et al.</i>: Silencing Alpha Synuclein in Mature Nigral Neurons Results in Rapid Neuroinflammation and Subsequent Toxicity. <i>Front Mol Neurosci.</i> 2018; <b>11</b>: 36. <a target=xrefwindow id=d47403e1962 href="http://www.ncbi.nlm.nih.gov/pubmed/29497361">PubMed Abstract </a> | <a target=xrefwindow id=d47403e1965 href="https://doi.org/10.3389/fnmol.2018.00036">Publisher Full Text </a> | <a target=xrefwindow id=d47403e1969 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5819572">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/732787291">Faculty Opinions Recommendation</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/730367900"><span class="faculty-opinion-icon small"></span></a><a name=d47403e1982 class=n-a></a>Mittal S, Bjrnevik K, Im DS, <i> et al.</i>: 2-Adrenoreceptor is a regulator of the -synuclein gene driving risk of Parkinson's disease. <i>Science.</i> 2017; <b>357</b>(6354): 8918. <a target=xrefwindow id=d47403e1993 href="http://www.ncbi.nlm.nih.gov/pubmed/28860381">PubMed Abstract </a> | <a target=xrefwindow id=d47403e1996 href="https://doi.org/10.1126/science.aaf3934">Publisher Full Text </a> | <a target=xrefwindow id=d47403e2000 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5761666">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/730367900">Faculty Opinions Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d47403e2013 class=n-a></a>Bertilsson G, Patrone C, Zachrisson O, <i> et al.</i>: Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. <i>J Neurosci Res.</i> 2008; <b>86</b>(2): 32638. <a target=xrefwindow id=d47403e2024 href="http://www.ncbi.nlm.nih.gov/pubmed/17803225">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2027 href="https://doi.org/10.1002/jnr.21483">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/1160337"><span class="faculty-opinion-icon small"></span></a><a name=d47403e2037 class=n-a></a>Li Y, Perry T, Kindy MS, <i> et al.</i>: GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. <i>Proc Natl Acad Sci U S A.</i> 2009; <b>106</b>(4): 128590. <a target=xrefwindow id=d47403e2048 href="http://www.ncbi.nlm.nih.gov/pubmed/19164583">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2051 href="https://doi.org/10.1073/pnas.0806720106">Publisher Full Text </a> | <a target=xrefwindow id=d47403e2055 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2633544">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/1160337">Faculty Opinions Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d47403e2068 class=n-a></a>Harkavyi A, Abuirmeileh A, Lever R, <i> et al.</i>: Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. <i>J Neuroinflammation.</i> 2008; <b>5</b>: 19. <a target=xrefwindow id=d47403e2079 href="http://www.ncbi.nlm.nih.gov/pubmed/18492290">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2082 href="https://doi.org/10.1186/1742-2094-5-19">Publisher Full Text </a> | <a target=xrefwindow id=d47403e2086 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2426681">Free Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d47403e2095 class=n-a></a>Athauda D, Foltynie T: The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: Mechanisms of action. <i>Drug Discov Today.</i> 2016; <b>21</b>(5): 80218. <a target=xrefwindow id=d47403e2103 href="http://www.ncbi.nlm.nih.gov/pubmed/26851597">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2106 href="https://doi.org/10.1016/j.drudis.2016.01.013">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d47403e2115 class=n-a></a>Aviles-Olmos I, Dickson J, Kefalopoulou Z, <i> et al.</i>: Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinsons Disease. <i>J Parkinsons Dis.</i> 2014; <b>4</b>(3): 33744. <a target=xrefwindow id=d47403e2126 href="http://www.ncbi.nlm.nih.gov/pubmed/24662192">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2129 href="https://doi.org/10.3233/JPD-140364">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/727879031"><span class="faculty-opinion-icon small"></span></a><a name=d47403e2138 class=n-a></a>Athauda D, Maclagan K, Skene SS, <i> et al.</i>: Exenatide once weekly versus placebo in Parkinson's disease: A randomised, double-blind, placebo-controlled trial. <i>Lancet.</i> 2017; <b>390</b>(10103): 166475. <a target=xrefwindow id=d47403e2149 href="http://www.ncbi.nlm.nih.gov/pubmed/28781108">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2152 href="https://doi.org/10.1016/S0140-6736(17)31585-4">Publisher Full Text </a> | <a target=xrefwindow id=d47403e2156 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5831666">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/727879031">Faculty Opinions Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d47403e2169 class=n-a></a>Karuppagounder SS, Brahmachari S, Lee Y, <i> et al.</i>: The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease. <i>Sci Rep.</i> 2014; <b>4</b>: 4874. <a target=xrefwindow id=d47403e2180 href="http://www.ncbi.nlm.nih.gov/pubmed/24786396">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2183 href="https://doi.org/10.1038/srep04874">Publisher Full Text </a> | <a target=xrefwindow id=d47403e2187 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4007078">Free Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/736616547"><span class="faculty-opinion-icon small"></span></a><a name=d47403e2197 class=n-a></a>Cai R, Zhang Y, Simmering JE, <i> et al.</i>: Enhancing glycolysis attenuates Parkinsons disease progression in models and clinical databases. <i>J Clin Invest.</i> 2019; <b>129</b>(10): 453949. <a target=xrefwindow id=d47403e2208 href="http://www.ncbi.nlm.nih.gov/pubmed/31524631">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2211 href="https://doi.org/10.1172/JCI129987">Publisher Full Text </a> | <a target=xrefwindow id=d47403e2215 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6763248">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/736616547">Faculty Opinions Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/731260266"><span class="faculty-opinion-icon small"></span></a><a name=d47403e2228 class=n-a></a>Coles LD, Tuite PJ, z G, <i> et al.</i>: Repeated-Dose Oral N-Acetylcysteine in Parkinson's Disease: Pharmacokinetics and Effect on Brain Glutathione and Oxidative Stress. <i>J Clin Pharmacol.</i> 2018; <b>58</b>(2): 15867. <a target=xrefwindow id=d47403e2239 href="http://www.ncbi.nlm.nih.gov/pubmed/28940353">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2242 href="https://doi.org/10.1002/jcph.1008">Publisher Full Text </a> | <a target=xrefwindow id=d47403e2246 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5762253">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/731260266">Faculty Opinions Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d47403e2259 class=n-a></a>Kosloski LM, Kosmacek EA, Olson KE, <i> et al.</i>: GM-CSF induces neuroprotective and anti-inflammatory responses in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxicated mice. <i>J Neuroimmunol.</i> 2013; <b>265</b>(12): 110. <a target=xrefwindow id=d47403e2270 href="http://www.ncbi.nlm.nih.gov/pubmed/24210793">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2273 href="https://doi.org/10.1016/j.jneuroim.2013.10.009">Publisher Full Text </a> | <a target=xrefwindow id=d47403e2277 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3872482">Free Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d47403e2286 class=n-a></a>Gendelman HE, Zhang Y, Santamaria P, <i> et al.</i>: Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial. <i>NPJ Parkinsons Dis.</i> 2017; <b>3</b>: 10. <a target=xrefwindow id=d47403e2297 href="http://www.ncbi.nlm.nih.gov/pubmed/28649610">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2300 href="https://doi.org/10.1038/s41531-017-0013-5 ">Publisher Full Text </a> | <a target=xrefwindow id=d47403e2304 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5445595">Free Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d47403e2313 class=n-a></a>Jucaite A, Svenningsson P, Rinne JO, <i> et al.</i>: Effect of the myeloperoxidase inhibitor AZD3241 on microglia: A PET study in Parkinson's disease. <i>Brain.</i> 2015; <b>138</b>(Pt 9): 2687700. <a target=xrefwindow id=d47403e2324 href="http://www.ncbi.nlm.nih.gov/pubmed/26137956">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2327 href="https://doi.org/10.1093/brain/awv184">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d47403e2336 class=n-a></a>Ilijic E, Guzman JN, Surmeier DJ: The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. <i>Neurobiol Dis.</i> 2011; <b>43</b>(2): 36471. <a target=xrefwindow id=d47403e2344 href="http://www.ncbi.nlm.nih.gov/pubmed/21515375">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2347 href="https://doi.org/10.1016/j.nbd.2011.04.007">Publisher Full Text </a> | <a target=xrefwindow id=d47403e2350 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3235730">Free Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d47403e2360 class=n-a></a>Martin-Bastida A, Ward RJ, Newbould R, <i> et al.</i>: Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinsons disease. <i>Sci Rep.</i> 2017; <b>7</b>(1): 1398. <a target=xrefwindow id=d47403e2371 href="http://www.ncbi.nlm.nih.gov/pubmed/28469157">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2374 href="https://doi.org/10.1038/s41598-017-01402-2">Publisher Full Text </a> | <a target=xrefwindow id=d47403e2378 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5431100">Free Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/726576364"><span class="faculty-opinion-icon small"></span></a><a name=d47403e2387 class=n-a></a>Pagan F, Hebron M, Valadez EH, <i> et al.</i>: Nilotinib Effects in Parkinsons disease and Dementia with Lewy bodies. <i>J Parkinsons Dis.</i> 2016; <b>6</b>(3): 50317. <a target=xrefwindow id=d47403e2398 href="http://www.ncbi.nlm.nih.gov/pubmed/27434297">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2401 href="https://doi.org/10.3233/JPD-160867">Publisher Full Text </a> | <a target=xrefwindow id=d47403e2405 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5008228">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/726576364">Faculty Opinions Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d47403e2418 class=n-a></a>Schwarzschild MA: Could MAO-B Inhibitor Withdrawal Rather than Nilotinib Benefit Explain the Dopamine Metabolite Increase in Parkinsonian Study Subjects? <i>J Parkinsons Dis.</i> 2017; <b>7</b>(1): 7980. <a target=xrefwindow id=d47403e2426 href="http://www.ncbi.nlm.nih.gov/pubmed/28035939">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2429 href="https://doi.org/10.3233/JPD-160975">Publisher Full Text </a> | <a target=xrefwindow id=d47403e2432 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5302030">Free Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/735389386"><span class="faculty-opinion-icon small"></span></a><a name=d47403e2441 class=n-a></a>Pagan FL, Hebron ML, Wilmarth B, <i> et al.</i>: Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease. <i>Pharmacol Res Perspect.</i> 2019; <b>7</b>(2): e00470. <a target=xrefwindow id=d47403e2452 href="http://www.ncbi.nlm.nih.gov/pubmed/30906562">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2455 href="https://doi.org/10.1002/prp2.470">Publisher Full Text </a> | <a target=xrefwindow id=d47403e2459 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6412143">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/735389386">Faculty Opinions Recommendation</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d47403e2472 class=n-a></a>Chen X, Zhao C, Li X, <i> et al.</i>: Terazosin activates Pgk1 and Hsp90 to promote stress resistance. <i>Nat Chem Biol.</i> 2015; <b>11</b>(1): 1925. <a target=xrefwindow id=d47403e2483 href="http://www.ncbi.nlm.nih.gov/pubmed/25383758">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2486 href="https://doi.org/10.1038/nchembio.1657">Publisher Full Text </a> | <a target=xrefwindow id=d47403e2490 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4412158">Free Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d47403e2499 class=n-a></a>Mortiboys H, Aasly J, Bandmann O: Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease. <i>Brain.</i> 2013; <b>136</b>(Pt 10): 303850. <a target=xrefwindow id=d47403e2507 href="http://www.ncbi.nlm.nih.gov/pubmed/24000005">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2510 href="https://doi.org/10.1093/brain/awt224">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d47403e2520 class=n-a></a>Mortiboys H, Furmston R, Bronstad G, <i> et al.</i>: UDCA exerts beneficial effect on mitochondrial dysfunction in <i>LRRK2<sup>G2019S</sup></i> carriers and <i>in vivo</i>. <i>Neurology.</i> 2015; <b>85</b>(10): 84652. <a target=xrefwindow id=d47403e2540 href="http://www.ncbi.nlm.nih.gov/pubmed/26253449">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2543 href="https://doi.org/10.1212/WNL.0000000000001905">Publisher Full Text </a> | <a target=xrefwindow id=d47403e2546 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4560055">Free Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d47403e2555 class=n-a></a>Abdelkader NF, Safar MM, Salem HA: Ursodeoxycholic Acid Ameliorates Apoptotic Cascade in the Rotenone Model of Parkinson's Disease: Modulation of Mitochondrial Perturbations. <i>Mol Neurobiol.</i> 2016; <b>53</b>(2): 8107. <a target=xrefwindow id=d47403e2563 href="https://doi.org/10.1007/s12035-014-9043-8">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/717997690"><span class="faculty-opinion-icon small"></span></a><a name=d47403e2572 class=n-a></a>Winder-Rhodes SE, Evans JR, Ban M, <i> et al.</i>: Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. <i>Brain.</i> 2013; <b>136</b>(Pt 2): 3929. <a target=xrefwindow id=d47403e2583 href="http://www.ncbi.nlm.nih.gov/pubmed/23413260">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2586 href="https://doi.org/10.1093/brain/aws318">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/717997690">Faculty Opinions Recommendation</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d47403e2599 class=n-a></a>Bras J, Paisan-Ruiz C, Guerreiro R, <i> et al.</i>: Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal. <i>Neurobiol Aging.</i> 2009; <b>30</b>(9): 15157. <a target=xrefwindow id=d47403e2610 href="http://www.ncbi.nlm.nih.gov/pubmed/18160183">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2613 href="https://doi.org/10.1016/j.neurobiolaging.2007.11.016">Publisher Full Text </a> | <a target=xrefwindow id=d47403e2617 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2736795">Free Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d47403e2626 class=n-a></a>Sidransky E, Nalls MA, Aasly JO, <i> et al.</i>: Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease. <i>N Engl J Med.</i> 2009; <b>361</b>(17): 165161. <a target=xrefwindow id=d47403e2637 href="http://www.ncbi.nlm.nih.gov/pubmed/19846850">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2640 href="https://doi.org/10.1056/NEJMoa0901281">Publisher Full Text </a> | <a target=xrefwindow id=d47403e2644 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2856322">Free Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/13356043"><span class="faculty-opinion-icon small"></span></a><a name=d47403e2653 class=n-a></a>Mazzulli JR, Xu YH, Sun Y, <i> et al.</i>: Gaucher disease glucocerebrosidase and -synuclein form a bidirectional pathogenic loop in synucleinopathies. <i>Cell.</i> 2011; <b>146</b>(1): 3752. <a target=xrefwindow id=d47403e2664 href="http://www.ncbi.nlm.nih.gov/pubmed/21700325">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2667 href="https://doi.org/10.1016/j.cell.2011.06.001">Publisher Full Text </a> | <a target=xrefwindow id=d47403e2671 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3132082">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/13356043">Faculty Opinions Recommendation</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d47403e2685 class=n-a></a>Fernandes HJR, Hartfield EM, Christian HC, <i> et al.</i>: ER Stress and Autophagic Perturbations Lead to Elevated Extracellular -Synuclein in <i>GBA-N370S</i> Parkinson's iPSC-Derived Dopamine Neurons. <i>Stem Cell Reports.</i> 2016; <b>6</b>(3): 34256. <a target=xrefwindow id=d47403e2699 href="http://www.ncbi.nlm.nih.gov/pubmed/26905200">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2703 href="https://doi.org/10.1016/j.stemcr.2016.01.013">Publisher Full Text </a> | <a target=xrefwindow id=d47403e2706 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4788783">Free Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d47403e2715 class=n-a></a>McNeill A, Magalhaes J, Shen C, <i> et al.</i>: Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. <i>Brain.</i> 2014; <b>137</b>(Pt 5): 148195. <a target=xrefwindow id=d47403e2726 href="http://www.ncbi.nlm.nih.gov/pubmed/24574503">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2729 href="https://doi.org/10.1093/brain/awu020">Publisher Full Text </a> | <a target=xrefwindow id=d47403e2733 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3999713">Free Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d47403e2742 class=n-a></a>Migdalska-Richards A, Daly L, Bezard E, <i> et al.</i>: Ambroxol effects in glucocerebrosidase and -synuclein transgenic mice. <i>Ann Neurol.</i> 2016; <b>80</b>(5): 76675. <a target=xrefwindow id=d47403e2753 href="http://www.ncbi.nlm.nih.gov/pubmed/27859541">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2756 href="https://doi.org/ 10.1002/ana.24790">Publisher Full Text </a> | <a target=xrefwindow id=d47403e2760 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5132106">Free Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/737204111"><span class="faculty-opinion-icon small"></span></a><a name=d47403e2769 class=n-a></a>Mullin S, Smith L, Lee K, <i> et al.</i>: Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial. <i>JAMA Neurol.</i> 2020; <b>77</b>(4): 427434. <a target=xrefwindow id=d47403e2780 href="http://www.ncbi.nlm.nih.gov/pubmed/31930374">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2783 href="https://doi.org/10.1001/jamaneurol.2019.4611">Publisher Full Text </a> | <a target=xrefwindow id=d47403e2787 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6990847">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/737204111">Faculty Opinions Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d47403e2800 class=n-a></a>Gegg ME, Sweet L, Wang BH, <i> et al.</i>: No evidence for substrate accumulation in Parkinson brains with <i>GBA</i> mutations. <i>Mov Disord.</i> 2015; <b>30</b>(8): 10859. <a target=xrefwindow id=d47403e2814 href="http://www.ncbi.nlm.nih.gov/pubmed/26096906">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2818 href="https://doi.org/10.1002/mds.26278">Publisher Full Text </a> | <a target=xrefwindow id=d47403e2821 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4529481">Free Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/726760306"><span class="faculty-opinion-icon small"></span></a><a name=d47403e2830 class=n-a></a>Snijders AH, Takakusaki K, Debu B, <i> et al.</i>: Physiology of freezing of gait. <i>Ann Neurol.</i> 2016; <b>80</b>(5): 64459. <a target=xrefwindow id=d47403e2841 href="http://www.ncbi.nlm.nih.gov/pubmed/27649270">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2844 href="https://doi.org/10.1002/ana.24778">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/726760306">Faculty Opinions Recommendation</a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d47403e2858 class=n-a></a>Caccia C, Maj R, Calabresi M, <i> et al.</i>: Safinamide: From molecular targets to a new anti-Parkinson drug. <i>Neurology.</i> 2006; <b>67</b>(7 Suppl 2): S18S23. <a target=xrefwindow id=d47403e2869 href="http://www.ncbi.nlm.nih.gov/pubmed/17030736">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2872 href="https://doi.org/10.1212/wnl.67.7_suppl_2.s18 ">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/735328024"><span class="faculty-opinion-icon small"></span></a><a name=d47403e2881 class=n-a></a>Elkouzi A, Vedam-Mai V, Eisinger RS, <i> et al.</i>: Emerging therapies in Parkinson disease  repurposed drugs and new approaches. <i>Nat Rev Neurol.</i> 2019; <b>15</b>(4): 204223. <a target=xrefwindow id=d47403e2892 href="http://www.ncbi.nlm.nih.gov/pubmed/30867588">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2895 href="https://doi.org/10.1038/s41582-019-0155-7">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/735328024">Faculty Opinions Recommendation</a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d47403e2908 class=n-a></a>Borgohain R, Szasz J, Stanzione P, <i> et al.</i>: Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. <i>Mov Disord.</i> 2014; <b>29</b>(2): 22937. <a target=xrefwindow id=d47403e2919 href="http://www.ncbi.nlm.nih.gov/pubmed/24323641">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2922 href="https://doi.org/10.1002/mds.25751">Publisher Full Text </a> | <a target=xrefwindow id=d47403e2926 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4285943">Free Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d47403e2935 class=n-a></a>Henderson EJ, Lord SR, Brodie MA, <i> et al.</i>: Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): A randomised, double-blind, placebo-controlled, phase 2 trial. <i> Lancet Neurol.</i> 2016; <b>15</b>(3): 24958. <a target=xrefwindow id=d47403e2946 href="http://www.ncbi.nlm.nih.gov/pubmed/26795874">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2949 href="https://doi.org/10.1016/S1474-4422(15)00389-0">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/5602956"><span class="faculty-opinion-icon small"></span></a><a name=d47403e2958 class=n-a></a>Chung KA, Lobb BM, Nutt JG, <i> et al.</i>: Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. <i>Neurology.</i> 2010; <b>75</b>(14): 12639. <a target=xrefwindow id=d47403e2969 href="http://www.ncbi.nlm.nih.gov/pubmed/20810998">PubMed Abstract </a> | <a target=xrefwindow id=d47403e2972 href="https://doi.org/10.1212/WNL.0b013e3181f6128c">Publisher Full Text </a> | <a target=xrefwindow id=d47403e2976 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3013493">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/5602956">Faculty Opinions Recommendation</a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d47403e2989 class=n-a></a>Yamada H, Aimi Y, Nagatsu I, <i> et al.</i>: Immunohistochemical detection of l-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats. <i>Neurosci Res.</i> 2007; <b>59</b>(1): 17. <a target=xrefwindow id=d47403e3000 href="http://www.ncbi.nlm.nih.gov/pubmed/17586078">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3003 href="https://doi.org/10.1016/j.neures.2007.05.002">Publisher Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d47403e3013 class=n-a></a>Bezard E, Tronci E, Pioli EY, <i> et al.</i>: Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. <i>Mov Disord.</i> 2013; <b>28</b>(8): 108896. <a target=xrefwindow id=d47403e3024 href="http://www.ncbi.nlm.nih.gov/pubmed/23389842">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3027 href="https://doi.org/10.1002/mds.25366">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/734541754"><span class="faculty-opinion-icon small"></span></a><a name=d47403e3036 class=n-a></a>Meadows SM, Conti MM, Gross L, <i> et al.</i>: Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats. <i>Mov Disord.</i> 2018; <b>33</b>(11): 17409. <a target=xrefwindow id=d47403e3047 href="http://www.ncbi.nlm.nih.gov/pubmed/30485908">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3050 href="https://doi.org/10.1002/mds.100">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/734541754">Faculty Opinions Recommendation</a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d47403e3063 class=n-a></a>Olanow CW, Damier P, Goetz CG, <i> et al.</i>: Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). <i>Clin Neuropharmacol.</i> 2004; <b>27</b>(2): 5862. <a target=xrefwindow id=d47403e3074 href="http://www.ncbi.nlm.nih.gov/pubmed/15252265">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3077 href="https://doi.org/10.1097/00002826-200403000-00003">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/734870877"><span class="faculty-opinion-icon small"></span></a><a name=d47403e3086 class=n-a></a>Sellnow RC, Newman JH, Chambers N, <i> et al.</i>: Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia. <i>Acta Neuropathol Commun.</i> 2019; <b>7</b>(1): 8. <a target=xrefwindow id=d47403e3097 href="http://www.ncbi.nlm.nih.gov/pubmed/30646956">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3100 href="https://doi.org/10.1186/s40478-018-0653-7">Publisher Full Text </a> | <a target=xrefwindow id=d47403e3104 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6332643">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/734870877">Faculty Opinions Recommendation</a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d47403e3117 class=n-a></a>Rosenblad C, Kirik D, Devaux B, <i> et al.</i>: Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. <i>Eur J Neurosci.</i> 1999; <b>11</b>(5): 155466. <a target=xrefwindow id=d47403e3128 href="http://www.ncbi.nlm.nih.gov/pubmed/10215908">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3131 href="https://doi.org/10.1046/j.1460-9568.1999.00566.x">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d47403e3140 class=n-a></a>Zhang Z, Miyoshi Y, Lapchak PA, <i> et al.</i>: Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. <i>J Pharmacol Exp Ther.</i> 1997; <b>282</b>(3): 1396401. <a target=xrefwindow id=d47403e3151 href="http://www.ncbi.nlm.nih.gov/pubmed/9316852">PubMed Abstract </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d47403e3161 class=n-a></a>Slevin JT, Gerhardt GA, Smith CD, <i> et al.</i>: Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell linederived neurotrophic factor. <i>J Neurosurg.</i> 2005; <b>102</b>(2): 21622. <a target=xrefwindow id=d47403e3172 href="http://www.ncbi.nlm.nih.gov/pubmed/15739547">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3175 href="https://doi.org/10.3171/jns.2005.102.2.0216">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d47403e3184 class=n-a></a>Patel NK, Bunnage M, Plaha P, <i> et al.</i>: Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: A two-year outcome study. <i>Ann Neurol.</i> 2005; <b>57</b>(2): 298302. <a target=xrefwindow id=d47403e3195 href="http://www.ncbi.nlm.nih.gov/pubmed/15668979">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3198 href="https://doi.org/10.1002/ana.20374">Publisher Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d47403e3207 class=n-a></a>Kirkeby A, Barker RA: Parkinson disease and growth factors  is GDNF good enough? <i>Nat Rev Neurol.</i> 2019; <b>15</b>(6): 3124. <a target=xrefwindow id=d47403e3215 href="http://www.ncbi.nlm.nih.gov/pubmed/30948845">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3218 href="https://doi.org/10.1038/s41582-019-0180-6">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d47403e3227 class=n-a></a>Lang AE, Gill S, Patel NK, <i> et al.</i>: Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. <i>Ann Neurol.</i> 2006; <b>59</b>(3): 45966. <a target=xrefwindow id=d47403e3238 href="http://www.ncbi.nlm.nih.gov/pubmed/16429411">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3241 href="https://doi.org/10.1002/ana.20737">Publisher Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/735165397"><span class="faculty-opinion-icon small"></span></a><a name=d47403e3250 class=n-a></a>Whone A, Luz M, Boca M, <i> et al.</i>: Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease. <i>Brain.</i> 2019; <b>142</b>(3): 51225. <a target=xrefwindow id=d47403e3261 href="http://www.ncbi.nlm.nih.gov/pubmed/30808022">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3264 href="https://doi.org/10.1093/brain/awz023">Publisher Full Text </a> | <a target=xrefwindow id=d47403e3268 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6391602">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/735165397">Faculty Opinions Recommendation</a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d47403e3281 class=n-a></a>Barker RA, Bjorklund A, Gash DM, <i> et al.</i>: GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. <i>J Parkinsons Dis.</i> 2020. <a target=xrefwindow id=d47403e3289 href="http://www.ncbi.nlm.nih.gov/pubmed/32508331">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3292 href="https://doi.org/10.3233/JPD-202004">Publisher Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d47403e3302 class=n-a></a>Marks Jr WJ, Ostrem JL, Verhagen L, <i> et al.</i>: Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: An open-label, phase I trial. <i>Lancet Neurol.</i> 2008; <b>7</b>(5): 4008. <a target=xrefwindow id=d47403e3313 href="http://www.ncbi.nlm.nih.gov/pubmed/18387850">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3316 href="https://doi.org/10.1016/S1474-4422(08)70065-6">Publisher Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/8159965"><span class="faculty-opinion-icon small"></span></a><a name=d47403e3325 class=n-a></a>Marks WJ, Bartus RT, Siffert J, <i> et al.</i>: Gene delivery of AAV2-neurturin for Parkinson's disease: A double-blind, randomised, controlled trial. <i>Lancet Neurol.</i> 2010; <b>9</b>(12): 116472. <a target=xrefwindow id=d47403e3336 href="http://www.ncbi.nlm.nih.gov/pubmed/20970382">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3339 href="https://doi.org/10.1016/S1474-4422(10)70254-4">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/8159965">Faculty Opinions Recommendation</a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d47403e3352 class=n-a></a>Olanow CW, Bartus RT, Baumann TL, <i> et al.</i>: Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. <i>Ann Neurol.</i> 2015; <b>78</b>(2): 24857. <a target=xrefwindow id=d47403e3363 href="http://www.ncbi.nlm.nih.gov/pubmed/26061140">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3366 href="https://doi.org/10.1002/ana.24436">Publisher Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d47403e3375 class=n-a></a>Bartus RT, Baumann TL, Siffert J, <i> et al.</i>: Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. <i>Neurology.</i> 2013; <b>80</b>(18): 1698701. <a target=xrefwindow id=d47403e3386 href="http://www.ncbi.nlm.nih.gov/pubmed/23576625">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3389 href="https://doi.org/10.1212/WNL.0b013e3182904faa">Publisher Full Text </a> | <a target=xrefwindow id=d47403e3393 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3716474">Free Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d47403e3402 class=n-a></a>Barker RA, Parmar M, Studer L, <i> et al.</i>: Human Trials of Stem Cell-Derived Dopamine Neurons for Parkinsons Disease: Dawn of a New Era. <i>Cell Stem Cell.</i> 2017; <b>21</b>(5): 56973. <a target=xrefwindow id=d47403e3413 href="http://www.ncbi.nlm.nih.gov/pubmed/29100010">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3416 href="https://doi.org/10.1016/j.stem.2017.09.014">Publisher Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/735158027"><span class="faculty-opinion-icon small"></span></a><a name=d47403e3425 class=n-a></a>Christine CW, Bankiewicz KS, van Laar AD, <i> et al.</i>: Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease. <i>Ann Neurol.</i> 2019; <b>85</b>(5): 70414. <a target=xrefwindow id=d47403e3436 href="http://www.ncbi.nlm.nih.gov/pubmed/30802998">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3439 href="https://doi.org/10.1002/ana.25450">Publisher Full Text </a> | <a target=xrefwindow id=d47403e3443 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6593762">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/735158027">Faculty Opinions Recommendation</a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/718235629"><span class="faculty-opinion-icon small"></span></a><a name=d47403e3457 class=n-a></a>Palfi S, Gurruchaga JM, Ralph GS, <i> et al.</i>: Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: A dose escalation, open-label, phase 1/2 trial. <i>Lancet.</i> 2014; <b>383</b>(9923): 113846. <a target=xrefwindow id=d47403e3468 href="http://www.ncbi.nlm.nih.gov/pubmed/24412048">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3471 href="https://doi.org/10.1016/S0140-6736(13)61939-X">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/718235629">Faculty Opinions Recommendation</a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d47403e3484 class=n-a></a>Lindvall O, Brundin P, Widner H, <i> et al.</i>: Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. <i>Science.</i> 1990; <b>247</b>(4942): 5747. <a target=xrefwindow id=d47403e3495 href="http://www.ncbi.nlm.nih.gov/pubmed/2105529">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3498 href="https://doi.org/10.1126/science.2105529">Publisher Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d47403e3507 class=n-a></a>Wenning GK, Odin P, Morrish P, <i> et al.</i>: Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. <i>Ann Neurol.</i> 1997; <b>42</b>(1): 95107. <a target=xrefwindow id=d47403e3518 href="http://www.ncbi.nlm.nih.gov/pubmed/9225690">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3521 href="https://doi.org/10.1002/ana.410420115">Publisher Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d47403e3530 class=n-a></a>Brundin P, Pogarell O, Hagell P, <i> et al.</i>: Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. <i>Brain.</i> 2000; <b>123</b>(Pt 7): 138090. <a target=xrefwindow id=d47403e3541 href="http://www.ncbi.nlm.nih.gov/pubmed/10869050">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3544 href="https://doi.org/10.1093/brain/123.7.1380">Publisher Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d47403e3553 class=n-a></a>Barker RA, Gtz M, Parmar M: New approaches for brain repairfrom rescue to reprogramming. <i>Nature.</i> 2018; <b>557</b>(7705): 32934. <a target=xrefwindow id=d47403e3561 href="http://www.ncbi.nlm.nih.gov/pubmed/29769670">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3564 href="https://doi.org/10.1038/s41586-018-0087-1">Publisher Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d47403e3573 class=n-a></a>Barker RA, Parmar M, Kirkeby A, <i> et al.</i>: Are Stem Cell-Based Therapies for Parkinson's Disease Ready for the Clinic in 2016? <i>J Parkinsons Dis.</i> 2016; <b>6</b>(1): 5763. <a target=xrefwindow id=d47403e3584 href="http://www.ncbi.nlm.nih.gov/pubmed/27003785">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3587 href="https://doi.org/10.3233/JPD-160798">Publisher Full Text </a> | <a target=xrefwindow id=d47403e3591 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4927930">Free Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d47403e3601 class=n-a></a>Cyranoski D: Trials of embryonic stem cells to launch in China. <i>Nature.</i> 2017; <b>546</b>(7656): 156. <a target=xrefwindow id=d47403e3609 href="http://www.ncbi.nlm.nih.gov/pubmed/28569831">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3612 href="https://doi.org/10.1038/546015a">Publisher Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d47403e3621 class=n-a></a>Kalia SK, Sankar T, Lozano AM: Deep brain stimulation for Parkinsons disease and other movement disorders. <i>Curr Opin Neurol.</i> 2013; <b>26</b>(4): 37480. <a target=xrefwindow id=d47403e3629 href="http://www.ncbi.nlm.nih.gov/pubmed/23817213">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3632 href="https://doi.org/10.1097/WCO.0b013e3283632d08">Publisher Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d47403e3641 class=n-a></a>Okun MS: Deep-brain stimulation--entering the era of human neural-network modulation. <i>N Engl J Med.</i> 2014; <b>371</b>(15): 136973. <a target=xrefwindow id=d47403e3649 href="http://www.ncbi.nlm.nih.gov/pubmed/25197963">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3652 href="https://doi.org/10.1056/NEJMp1408779">Publisher Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d47403e3661 class=n-a></a>Williams A, Gill S, Varma T, <i> et al.</i>: Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): A randomised, open-label trial. <i>Lancet Neurol.</i> 2010; <b>9</b>(6): 58191. <a target=xrefwindow id=d47403e3672 href="http://www.ncbi.nlm.nih.gov/pubmed/20434403">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3675 href="https://doi.org/10.1016/S1474-4422(10)70093-4">Publisher Full Text </a> | <a target=xrefwindow id=d47403e3679 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2874872">Free Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/3518958"><span class="faculty-opinion-icon small"></span></a><a name=d47403e3688 class=n-a></a>Follett KA, Weaver FM, Stern M, <i> et al.</i>: Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. <i>N Engl J Med.</i> 2010; <b>362</b>(22): 207791. <a target=xrefwindow id=d47403e3699 href="http://www.ncbi.nlm.nih.gov/pubmed/20519680">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3702 href="https://doi.org/10.1056/NEJMoa0907083">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/3518958">Faculty Opinions Recommendation</a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d47403e3715 class=n-a></a>Grabli D, Karachi C, Folgoas E, <i> et al.</i>: Gait disorders in parkinsonian monkeys with pedunculopontine nucleus lesions: A tale of two systems. <i>J Neurosci.</i> 2013; <b>33</b>(29): 1198693. <a target=xrefwindow id=d47403e3726 href="http://www.ncbi.nlm.nih.gov/pubmed/23864685">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3729 href="https://doi.org/10.1523/JNEUROSCI.1568-13.2013">Publisher Full Text </a> | <a target=xrefwindow id=d47403e3733 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6794061">Free Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/733525407"><span class="faculty-opinion-icon small"></span></a><a name=d47403e3743 class=n-a></a>Hacker ML, DeLong MR, Turchan M, <i> et al.</i>: Effects of deep brain stimulation on rest tremor progression in early stage Parkinson disease. <i>Neurology.</i> 2018; <b>91</b>(5): e463e471. <a target=xrefwindow id=d47403e3754 href="http://www.ncbi.nlm.nih.gov/pubmed/29959266">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3757 href="https://doi.org/10.1212/WNL.0000000000005903">Publisher Full Text </a> | <a target=xrefwindow id=d47403e3761 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6093763">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/733525407">Faculty Opinions Recommendation</a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d47403e3774 class=n-a></a>Hickey P, Stacy M: Deep Brain Stimulation: A Paradigm Shifting Approach to Treat Parkinson's Disease. <i>Front Neurosci.</i> 2016; <b>10</b>: 173. <a target=xrefwindow id=d47403e3782 href="http://www.ncbi.nlm.nih.gov/pubmed/27199637">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3785 href="https://doi.org/10.3389/fnins.2016.00173">Publisher Full Text </a> | <a target=xrefwindow id=d47403e3788 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4848307">Free Full Text </a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a name=d47403e3797 class=n-a></a>Stefani A, Lozano AM, Peppe A, <i> et al.</i>: Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. <i>Brain.</i> 2007; <b>130</b>(Pt 6): 1596607. <a target=xrefwindow id=d47403e3808 href="http://www.ncbi.nlm.nih.gov/pubmed/17251240">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3811 href="https://doi.org/10.1093/brain/awl346">Publisher Full Text </a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/718019580"><span class="faculty-opinion-icon small"></span></a><a name=d47403e3820 class=n-a></a>Weiss D, Walach M, Meisner C, <i> et al.</i>: Nigral stimulation for resistant axial motor impairment in Parkinsons disease?: A randomized controlled trial. <i>Brain.</i> 2013; <b>136</b>(Pt 7): 2098108. <a target=xrefwindow id=d47403e3831 href="http://www.ncbi.nlm.nih.gov/pubmed/23757762">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3834 href="https://doi.org/10.1093/brain/awt122">Publisher Full Text </a> | <a target=xrefwindow id=d47403e3838 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3692032">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/718019580">Faculty Opinions Recommendation</a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/732327234"><span class="faculty-opinion-icon small"></span></a><a name=d47403e3851 class=n-a></a>Gratwicke J, Zrinzo L, Kahan J, <i> et al.</i>: Bilateral Deep Brain Stimulation of the Nucleus Basalis of Meynert for Parkinson Disease Dementia: A Randomized Clinical Trial. <i>JAMA Neurol.</i> 2018; <b>75</b>(2): 16978. <a target=xrefwindow id=d47403e3862 href="http://www.ncbi.nlm.nih.gov/pubmed/29255885">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3865 href="https://doi.org/10.1001/jamaneurol.2017.3762">Publisher Full Text </a> | <a target=xrefwindow id=d47403e3869 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5838617">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/732327234">Faculty Opinions Recommendation</a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/732665403"><span class="faculty-opinion-icon small"></span></a><a name=d47403e3882 class=n-a></a>Samotus O, Parrent A, Jog M: Spinal Cord Stimulation Therapy for Gait Dysfunction in Advanced Parkinson's Disease Patients. <i>Mov Disord.</i> 2018; <b>33</b>(5): 78392. <a target=xrefwindow id=d47403e3890 href="http://www.ncbi.nlm.nih.gov/pubmed/29442369">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3893 href="https://doi.org/10.1002/mds.27299">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/732665403">Faculty Opinions Recommendation</a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d47403e3907 class=n-a></a>Quinn EJ, Blumenfeld Z, Velisar A, <i> et al.</i>: Beta oscillations in freely moving Parkinson's subjects are attenuated during deep brain stimulation. <i>Mov Disord.</i> 2015; <b>30</b>(13): 17508. <a target=xrefwindow id=d47403e3918 href="http://www.ncbi.nlm.nih.gov/pubmed/26360123">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3921 href="https://doi.org/10.1002/mds.26376">Publisher Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d47403e3930 class=n-a></a>Grossman N, Bono D, Dedic N, <i> et al.</i>: Noninvasive Deep Brain Stimulation via Temporally Interfering Electric Fields. <i>Cell.</i> 2017; <b>169</b>(6): 10291041.e16. <a target=xrefwindow id=d47403e3941 href="http://www.ncbi.nlm.nih.gov/pubmed/28575667">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3944 href="https://doi.org/10.1016/j.cell.2017.05.024">Publisher Full Text </a> | <a target=xrefwindow id=d47403e3948 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5520675">Free Full Text </a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/737080731"><span class="faculty-opinion-icon small"></span></a><a name=d47403e3957 class=n-a></a>Xu Y, He Q, Wang M, <i> et al.</i>: Safety and efficacy of magnetic resonance imaging-guided focused ultrasound neurosurgery for Parkinson's disease: A systematic review. <i>Neurosurg Rev.</i> 2019. <a target=xrefwindow id=d47403e3965 href="http://www.ncbi.nlm.nih.gov/pubmed/31814058">PubMed Abstract </a> | <a target=xrefwindow id=d47403e3968 href="https://doi.org/10.1007/s10143-019-01216-y">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/737080731">Faculty Opinions Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 31 Jul 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-862/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-862/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Forvie Site, Robinson Way, Cambridge, CB2 0PY, UK<br/> <sup>2</sup> Department of Neurology, Norfolk and Norwich University Hospital, Norwich, UK<br/> <sup>3</sup> Wellcome Trust &ndash; Medical Research Council Stem Cell Institute, University of Cambridge, Cambridge, UK<br/> <p> <div class=margin-bottom> Thomas B Stoker <br/> <span>Roles: </span> Conceptualization, Writing  Original Draft Preparation, Writing  Review & Editing </div> <div class=margin-bottom> Roger A Barker <br/> <span>Roles: </span> Conceptualization, Supervision, Writing  Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/9-862/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 31 Jul 2020, 9:862 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.25634.1">https://doi.org/10.12688/f1000research.25634.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden">  2020 Stoker TB and Barker RA. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=28292 data-id=25634 data-downloads="" data-views="" data-scholar="10.12688/f1000research.25634.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/9-862/v1/pdf?article_uuid=c706e5aa-67f6-4d88-9eaf-602285070cca" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.25634.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Stoker TB and Barker RA. Recent developments in the treatment of Parkinson's Disease [version 1; peer review: 2 approved] <i>F1000Research</i> 2020, <b>9</b>(Faculty Rev):862 (<a href="https://doi.org/10.12688/f1000research.25634.1" target=_blank>https://doi.org/10.12688/f1000research.25634.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=25634 id=mobile-track-article-signin-25634 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/25634?target=/articles/9-862/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=28292 /> <input name=articleId type=hidden value=25634 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Tipu Z. Aziz</strong>, Nuffield Department of Clinical Neurosciences, University of Oxford, UK </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Fredric P. Manfredsson</strong>, Parkinson's Disease Research Unit, Department of Neurobiology, Barrow Neurological Institute, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 31 Jul 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-862/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-862/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=34838-68463></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=73309-68462></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/9-862/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>31 Jul 20</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Tipu Z. Aziz</strong>, Nuffield Department of Clinical Neurosciences, University of Oxford, UK </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Fredric P. Manfredsson</strong>, Parkinson's Disease Research Unit, Department of Neurobiology, Barrow Neurological Institute, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/9-862/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/9-862/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent developments in the treatment of Parkinson\'s...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/9-862/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/9-862/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/9-862/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Stoker TB and Barker RA');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/9-862/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/9-862",
            templates : {
                twitter : "Recent developments in the treatment of Parkinson\'s Disease. Stoker TB and Barker RA, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/9-862/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent developments in the treatment of Parkinson\'s Disease", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent developments in the treatment of Parkinson\'s Disease", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/25634/28292")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "28292");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "68463": 1,
                           "68462": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "c85df047-39dd-4ad3-9b10-904eef74f417";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-862.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-862.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-862.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/9-862.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/9-862.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>